documents incorporated reference portions proxy statement registrants annual meeting stockholders held may filed within days conclusion registrant 's fiscal year ended december incorporated reference part iii annual report bristolmyers squibb company index december part item business acquisitions divestitures products intellectual property product exclusivity research development alliances marketing distribution customers competition pricing price constraints market access government regulation sources availability raw materials manufacturing quality assurance environmental regulation employees foreign operations bristolmyers squibb website item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ia executive officers registrant part ii item market registrant 's common stock stockholder matters item selected financial data item management 's discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data consolidated statements earnings comprehensive income consolidated balance sheets consolidated statements cash flows notes financial statements item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item auditor fees part iv item exhibits financial statement schedule item summary signatures summary abbreviated terms exhibit index indicates brand names products trademarks owned bms specific trademark ownership information included exhibit indexpart item business general bristolmyers squibb company incorporated laws state delaware august name bristolmyers company successor new york business started bristolmyers company changed name bristolmyers squibb company result merger engaged discovery development licensing manufacturing marketing distribution sale biopharmaceutical products global basis refer summary abbreviated terms end terms used throughout document operate one segmentbiopharmaceuticals additional information business segments refer item financial statementsnote business segment information compete worldwide researchbased drug companies smaller research companies generic drug manufacturers products sold worldwide primarily wholesalers retail pharmacies hospitals government entities medical profession manufacture products us puerto rico four foreign countries revenues come products following therapeutic classes oncology cardiovascular immunoscience virology including hiv infection percentage revenues significant regioncountry follows year ended december dollars millions united states europe japan total revenues acquisitions divestitures acquisitions last five years include ifm cormorant padlock cardioxyl flexus ipierian also entered several license collaboration arrangements divestitures last five years include small molecule manufacturing operations swords ireland certain otc brands investigational hiv medicines businesses erbitux north america certain mature otc brands businesses diabetes business also outlicensed genetically defined disease investigational compounds transactions continue allow us focus resources behind growth opportunities drive greatest longterm value products intellectual property product exclusivity pharmaceutical products include chemicallysynthesized small molecule drugs products produced biological processes called biologics small molecule drugs typically administered orally eg form pill tablet although drug delivery mechanisms used well biologics typically administered patients injections intravenous infusion product summary including approved indications information alliance arrangements products refer alliances item financial statementsnote alliances opdivo opdivo biological product fully human monoclonal antibody binds pd nkt cells opdivo received approvals several anticancer indications including bladder blood colon head neck kidney liver lung melanoma stomach opdivoyervoy regimen also approved multiple markets treatment melanoma several ongoing potentially registrational studies opdivo across tumor types disease areas monotherapy combination yervoy various anticancer agents eliquis eliquis oral factor xa inhibitor targeted stroke prevention atrial fibrillation prevention treatment vte disorders orencia orencia biological product fusion protein novel immunosuppressive activity targeted initially adult patients moderately severely active ra psa inadequate response certain currently available treatments orencia also indicated certain pediatric patients moderately severely active polyarticular juvenile idiopathic arthritis sprycel sprycel multitargeted tyrosine kinase inhibitor approved firstline treatment adults philadelphia chromosomepositive cml chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy including gleevec imatinib mesylate treatment children philadelphia chromosome positive cml chronic phase yervoy yervoy biological product monoclonal antibody treatment adults pediatric patients unresectable metastatic melanoma well adjuvant treatment patients melanoma undergone complete resection empliciti empliciti biological product humanized monoclonal antibody treatment multiple myeloma baraclude baraclude potent selective inhibitor hepatitis b virus sustiva franchise sustiva franchise includes sustiva nonnucleoside reverse transcriptase inhibitor treatment hiv well bulk efavirenz included combination therapy atripla reyataz franchise reyataz franchise includes reyataz protease inhibitor treatment hiv combination therapy evotaz combining reyataz gilead 's tybost hepatitis c franchise daklinza daclatasvir dcv oral small molecule nsa replication complex inhibitor treatment hcv sunvepra asunaprevir asv oral small molecule ns protease inhibitor treatment hcv part dual regimen dcvasv japan china license number patents us foreign countries primarily covering products also developed many brand names trademarks products consider overall protection patents trademarks licenses intellectual property rights material value act protect rights infringement pharmaceutical industry majority innovative products commercial value usually realized period product market exclusivity products market exclusivity generally determined two forms intellectual property patent rights held innovator company regulatory forms exclusivity innovative drug entitled patents key determinant market exclusivity branded pharmaceuticals patents provide innovator right exclude others practicing invention related medicine patents may cover among things active ingredients various uses drug product pharmaceutical formulations drug delivery mechanisms processes intermediates useful manufacture products protection individual products extends varying periods accordance expiration dates patents various countries protection afforded may also vary country country depends upon type patent scope coverage availability meaningful legal remedies country market exclusivity also sometimes influenced regulatory data protection exclusivity rights many developed countries provide certain nonpatent incentives development medicines example us eu japan certain countries regulatory data protection exclusivity rights offered incentives research medicines rare diseases orphan drugs medicines useful treating pediatric patients incentives provide market exclusivity period product expires beyond patent term us eu japan provide regulatory data protection period time approval new drug regulatory agency may rely upon innovators data approve competitors generic copy certain markets patent protection forms market exclusivity may expired regulatory data protection particular importance however regulatory forms exclusivity prevent competitor gaining regulatory approval prior expiration regulatory data protection exclusivity basis competitors safety efficacy data drug even drug identical marketed innovator patent rights forms exclusivity expire generic versions medicine approved marketed often substantial rapid declines sales original innovative product discussion impact generic competition business refer generic competition specific aspects law governing market exclusivity data regulatory protection pharmaceuticals vary country country following summarizes key exclusivity rules markets representing significant sales united states us key products protected patents varying terms depending type patent filing date significant portion products patent life however lost time takes innovative company develop obtain regulatory approval new drug compensation least part lost patent term due regulatory review periods innovator may depending number factors apply government restore lost patent term extending expiration date one patent maximum term five years provided extension cause patent effect years date drug approval company seeking market innovative pharmaceutical us must submit complete set safety efficacy data fda innovative pharmaceutical chemical product company files nda medicine biological product bla filed type application filed affects regulatory data protection exclusivity rights chemical products competitor seeking launch generic substitute chemical innovative drug us must file anda fda anda generic manufacturer needs demonstrate bioequivalence generic substitute approved nda drug anda relies upon safety efficacy data previously filed innovator nda innovator company required list certain patents covering medicine fda commonly known orange book absent successful patent challenge fda approve anda innovators listed patents expire however innovator marketed product four years generic manufacturer may file anda allege one patents listed orange book innovators nda either invalid infringed allegation commonly known paragraph iv certification innovator must decide whether file patent infringement suit generic manufacturer time time andas including paragraph iv certifications filed respect certain products evaluate andas casebycase basis warranted file suit generic manufacturer protect patent rights addition patent protection certain innovative pharmaceutical products receive periods regulatory exclusivity nda designated orphan drug receive seven years exclusivity orphan indication time period neither ndas andas drug product approved orphan use company may also earn six months additional exclusivity drug specific clinical studies conducted written request fda study use medicine treat pediatric patients submission fda made prior loss basic exclusivity medicines approved nda also receive several types regulatory data protection innovative chemical pharmaceutical product entitled five years regulatory data protection us fda approve generic substitutes innovators patent challenged described generic manufacturer may file anda fourth year fiveyear regulatory data protection period pharmaceutical drug product contains active ingredient previously approved nda approved new formulation drug new indication basis new clinical studies may receive three years regulatory data protection formulation indication biologic products us healthcare legislation enacted created approval pathway biosimilar versions innovative biological products previously exist prior time innovative biologics essentially unlimited regulatory exclusivity new regulatory mechanism fda approve products similar generic copies innovative biologics basis less extensive data required full bla innovator marketed product four years manufacturer may file application approval biosimilar version innovator product however although application approval biosimilar may filed four years approval innovator product qualified innovative biological products receive years regulatory exclusivity meaning fda may approve biosimilar version years innovative biological product first approved fda law also provides mechanism innovators enforce patents protect innovative biological products biosimilar applicants challenge patents patent litigation may begin early four years innovative biological product first approved fda us increased likelihood generic biosimilar challenges innovators intellectual property increased risk loss innovators market exclusivity first generic companies increasingly sought challenge innovators basic patents covering major pharmaceutical products second statutory regulatory provisions us limit ability innovator company prevent generic biosimilar drugs approved launched patent litigation ongoing result developments possible predict length market exclusivity particular product certainty based solely expiration relevant patents current forms regulatory exclusivity european union patents pharmaceutical products generally enforceable eu us may extended compensate patent term lost regulatory review process extensions granted countrybycountry basis primary route use obtain marketing authorization pharmaceutical products eu centralized procedure procedure compulsory certain pharmaceutical products particular using biotechnological processes also available certain new chemical compounds products company seeking market innovative pharmaceutical product centralized procedure must file complete set safety data efficacy data part maa ema ema evaluates maa provides recommendation ec ec approves denies maa also possible new chemical products obtain marketing authorization eu mutual recognition procedure application made single member state member state approves pharmaceutical product national procedure applicant may submit approval mutual recognition procedure member states obtaining marketing authorization approval company must obtain pricing reimbursement pharmaceutical product typically subject member state law certain eu countries process take place simultaneously product marketed eu countries process must completed company market new product pricing reimbursement procedure take months sometimes years complete throughout eu products marketing authorizations filed octobernovember subject regime eight years innovator received first community authorization medicinal product generic company may file marketing authorization application product health authorities marketing authorization application approved generic company may commercialize product either years elapsed initial marketing authorization granted innovator possible extension years available innovator first eight years marketing authorization obtains additional indication significant clinical benefit comparison existing treatments products filed prior octobernovember year period data protection centralized procedures period either six years mutual recognition procedure depending member state contrast us patents eu listed regulatory authorities generic versions pharmaceutical products approved data protection expires regardless whether innovator holds patents covering drug thus possible innovator may seeking enforce patents generic competitor already marketing product also european patent system opposition procedure generic manufacturers may challenge validity patents covering innovator products within nine months grant general eu law treats chemicallysynthesized drugs biologicallyderived drugs respect intellectual property data protection addition relevant legislation annexes related biologic medicinal products ema issued guidelines outline additional information provided biosimilar products also known generic biologics order review application marketing approval japan japan medicines new chemical entities generally afforded eight years data exclusivity approved indications dosage patents pharmaceutical products enforceable generic copies receive regulatory approval data exclusivity patent expirations us patents japan may extended compensate patent term lost regulatory review process general japanese law treats chemicallysynthesized biologicallyderived drugs respect intellectual property market exclusivity rest world countries outside us eu japan wide variety legal systems respect intellectual property market exclusivity pharmaceuticals developed countries utilize systems similar either us eu among developing countries adopted patent laws andor regulatory exclusivity laws others developing countries formally adopted laws order comply wto commitments taken steps implement laws meaningful way enforcement wto actions long process governments assurance outcome thus assessing likely future market exclusivity innovative drugs developing countries take account formal legal rights political factors well following chart shows key products together year earliest basic exclusivity loss patent rights data exclusivity occurred currently estimated occur us eu japan also sell pharmaceutical products countries however data provided country bycountry basis individual country revenues significant outside us eu japan many instances basic exclusivity loss date listed expiration date patent claims active ingredient drug method using drug approved indication one approved indication instances basic exclusivity loss date listed chart expiration date data exclusivity period situations data exclusivity without patent protection competitor could seek regulatory approval submitting clinical study data obtain marketing approval prior expiration data exclusivity estimate market exclusivity period products purpose business planning length market exclusivity products impossible predict certainty complex interaction patent regulatory forms exclusivity inherent uncertainties regarding patent litigation assurance particular product enjoy market exclusivity full period time appears estimate exclusivity limited estimate total revenues product estimated loe dollars millions us eu japan prioritized brands opdivo nivolumab eliquis apixaban b orencia abatacept c sprycel dasatinib yervoy ipilimumab e empliciti elotuzumab f established brands baraclude entecavir sustiva efavirenz franchise g reyataz atazanavir sulfate franchise h hepatitis c franchise note estimated year basic loe table includes granted extensions patent term restoration ptr andor six months pediatric extensions obtained may laterexpiring patents cover particular forms compositions methods manufacturing methods using drug may result favorable market position products product exclusivity predicted assured regulatory data protection rdp may obtained described detail products intellectual property product exclusivity section references eu throughout include eu member states year ended december basic patent applications may filed current member states listed products instances date basic exclusivity loss different various eu member states currently market product country region indicated february epo board appeal revoked eu composition matter com patent february epo board appeal reversed remanded invalidity decision use dasatinib treat cml epos opposition division revoked october refer item financial statementsnote legal proceedings contingencies information opdivo bms jointly owns patent ono covering nivolumab com expires us eu ptrs filed granted expire us eu com patent covering nivolumab japan expires including granted ptr b eliquis loe based upon com patent expires us eu japan including granted ptr bms received paragraph iv certifications twentyfive anda filers initiated us hatch waxman patent litigation april bms settled several anda filers eu countries granted ptr com patent expires c orencia com patent including ptr expires us eu us eu method use patents covering indications expire japan loe based rdp exclusivity expires formulation additional patents directed abatacept expire beyond bms aware orencia biosimilar market us eu japan sprycel us com patent including ptr expires june bms entered settlement agreement apotex regarding patent infringement suit covering monohydrate form dasatinib whereby apotex launch generic dasatinib monohydrate anda product september earlier certain circumstances japan com patent expires rdp expires information eu countries see footnote e yervoy us japan loe based com patent expires including granted ptrs eu com patent expires including ptr granted countries however countries ptr granted com patent expire rdp expires us eu f empliciti loe period us eu japan based rdp exclusivity ptrs filed us eu japan granted expire bms commercialization agreement abbvie empliciti abbvie owns com patent covering elotuzumab expires us eu japan excluding potential ptrs information arrangement abbvie refer alliances item financial statementsnote alliances g sustiva franchise exclusivity period relates sustiva brand include exclusivity related combination therapy us loe efavirenz occurred december h reyataz eu market exclusivity projected expire com patent including ptr expired us expires eu hepatitis c franchise relates products including daclatasvir daklinza brand us loe based com patent expiry pending ptr granted expiry europe loe based com patent expiry however ptr granted many countries expire japan com patent expires including granted ptr research development rd critical longterm competitiveness concentrate rd efforts following disease areas significant unmet medical needs oncology including io immunoscience priorities lupus ra inflammatory bowel disease cardiovascular priority heart disease fibrotic disease priorities lung ipf liver nash also continue analyze may selectively pursue promising leads areas addition discovering developing new molecular entities look ways expand value existing products new indications formulations provide additional benefits patients order new drug reach market industry practice government regulations us eu foreign countries provide determination drugs effectiveness safety preclinical tests controlled clinical evaluation clinical development potential new drug typically includes phase phase ii phase iii clinical studies designed specifically support new drug application particular indication assuming studies successful phase clinical studies involve small number healthy volunteers patients suffering indicated disease test safety proper dosing phase ii clinical studies involve larger patient population investigate side effects efficacy optimal dosage drug candidate phase iii clinical studies conducted confirm phase ii results significantly larger patient population longer term provide reliable conclusive data regarding safety efficacy drug candidate although regulatory approval typically based results phase iii clinical studies times approval granted based data earlier studies consider registrational studies significant rd programs programs may include investigational compounds phases ii iii development initial indications marketed products development additional indications formulations expanding currently marketed products particularly opdivo combination yervoy agents first secondline therapy new indications substantial portion rd program strategy drug development time consuming expensive risky rd process typically takes fourteen years approximately two half years often spent phase iii latestage development average one chemical compounds discovered pharmaceutical industry researchers proves medically effective safe enough become approved medicine drug candidates fail stage process even latestage product candidates sometimes fail receive regulatory approval according kmr group based industry success rates approximately compounds enter phase development fail achieve regulatory approval compounds enter phase ii development failure rate approximately approximately fail phase iii development total rd expenses include costs discovery research preclinical development early latestage clinical development drug formulation well postcommercialization medical support marketed products proportionate allocations enterprisewide costs licensing acquiring assets rd expenses billion billion billion including license asset acquisition charges approximately billion million billion respectively end employed approximately people rd related support activities including substantial number physicians scientists holding graduate postgraduate degrees higherskilled technical personnel manage rd programs portfolio basis investing resources stage rd early discovery latestage development continually evaluate portfolio rd assets ensure appropriate balance earlystage latestage programs support future growth company spending latestage development programs represented approximately annual rd expenses last three years opdivo individual investigational compound marketed product represent rd expenses last three years part operating model evolution rd geographic footprint significantly transform foster speed innovation future transformation involves closing hopewell new jersey wallingford connecticut rd sites accompanied additional investment expansion opening others example expanding lawrenceville new jersey redwood city california sites plan open new rd facility cambridge massachusetts supplement internal drug discovery development programs alliances collaborative agreements help us bring new molecular agents capabilities platforms pipeline management continues emphasize leadership innovation productivity quality strategies success rd activities listed investigational compounds clinical studies well approved potential indications marketed products related therapeutic area january whether listed compounds ultimately becomes marketed product depends results clinical studies competitive landscape potential products market reimbursement decisions payers manufacturing processes necessary produce potential product commercial scale among factors assurance seek regulatory approval compounds approval sought obtained also assurance compound gets approved commercially successful stage development determine intellectual property issues patent protection may may available investigational compounds february following potential registrational study readouts opdivo anticipated tumor study details tumor study details cm opdivo yervoy st line part cm opdivo yervoy st line nonsmall cell lung cm opdivo chemo st line part head neck cancer cm opdivo yervoy st line cancer cmla opdivo yervoy chemo st line cm opdivo nd line hepatocellular small cell lung cancer cm opdivo yervoy st line maintenance cm opdivo st line carcinoma gastric cancer cm opdivo yervoy chemo st line key phase ii phase iii alliances enter alliances third parties transfer rights develop manufacture market andor sell pharmaceutical products alliances include licensing codevelopment comarketing copromotion arrangements joint ventures alliances involve sharing research development costs risk incurring research development expenses compounds lead revenuegenerating products reduced however profitability alliance products generally lower profits alliance products shared alliance partners actively pursue arrangements view alliances important complement discovery development commercialization activities alliance arrangements contain customary early termination provisions following material breaches bankruptcy product safety concerns amount notice required early termination generally ranges immediately upon notice days receipt notice termination immediately upon notice generally available party files voluntary bankruptcy petition material safety issue arises product medical riskbenefit incompatible welfare patients continue develop commercialize product termination notice period generally available involuntary bankruptcy petition filed dismissed material breach party occurred cured alliance agreements also permit us terminate without cause typically exercisable substantial advance written notice sometimes exercisable specified period time elapsed alliance agreement signed alliances typically otherwise contain provisions provide party right terminate alliance typically retain rights another party 's product intellectual property alliance terminates loss rights one products marketed sold us pursuant alliance could material results operations cash flows could material financial condition liquidity customary pharmaceutical industry terms alliances generally coextensive exclusivity period may vary country bycountry basis significant alliances currently marketed products investigational compounds described refer item financial statementsnote alliances additional information alliance agreements well alliance agreements pfizer bms pfizer jointly develop commercialize eliquis bms recognizes net product sales markets worldwide profits losses shared equally except certain countries pfizer commercializes eliquis pays bms salesbased fee otsuka bms otsuka jointly promote sprycel us eu bms recognizes net product sales salesbased fee paid otsuka ono bms exclusive right develop manufacture commercialize opdivo worldwide except japan south korea taiwan bms recognizes net product sales pays ono royalties north america applicable territories excluding three countries listed subject customary adjustments bms ono jointly develop commercialize opdivo yervoy several bms investigational compounds japan south korea taiwan bms responsible supply products profits losses development costs shared equally combination therapies involving compounds parties otherwise sharing activities involving one partys compounds bms ono also jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulations jointly promoted assigned customer accounts bms responsible product supply copromotion fee paid sale made partys assigned customer abbvie bms abbvie jointly develop empliciti abbvie funds global development costs bms solely responsible supply distribution sales marketing activities recognizes net product sales abbvie shares profits losses us paid tiered royalties outside us gilead bms gilead formed joint venture develop commercialize atripla us canada europe bms recognizes alliance revenue bulk efavirenz component atripla upon sales atripla thirdparty customers december gilead terminated bms 's participation us joint venture included us canada markets following launch generic version sustiva us bms receive sales based fee gilead net sales atripla us licensing arrangements inlicensing outlicensing arrangements without active participation parties including obtained acquisitions typically entitled receive obligated pay contingent milestone payments well royalties products commercialized marketing distribution customers promote appropriate use products directly healthcare professionals organizations doctors nurse practitioners physician assistants pharmacists technologists hospitals pbms mcos also provide information appropriate use products consumers us directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceuticals refer government regulation field sales medical organizations explain risks benefits approved uses products medical professionals work gain access products formularies reimbursement plans lists recommended approved medicines products including medicare part plans providing information clinical profiles products marketing sales prescription pharmaceuticals limited approved uses particular product continue develop scientific data information potential additional uses products provide information scientific exchange scientific congresses share information products appropriate ways including development publications response unsolicited inquiries doctors medical professionals mcos operations include several marketing sales organizations product marketing organization supported sales force may responsible selling one products also marketing organizations focus certain classes customers managed care entities certain types marketing tools digital consumer communications sales forces focus communicating information new approved products uses well approved uses established products promotion physicians increasingly targeted physician specialists treat patients need medicines products sold principally wholesalers specialty distributors lesser extent directly distributors retailers hospitals clinics government agencies pharmacies refer item financial statementsnote business segment information gross revenues three largest pharmaceutical wholesalers us percentage global gross revenues us business dsas substantially direct wholesaler distributor customers allow us monitor us wholesaler distributor inventory levels requires wholesalers distributors maintain inventory levels one month demand dsas including three largest wholesalers expired december entered letters agreement three largest wholesalers specialty distributor affiliates extend current agreements march enter final agreements december prior expiration letters agreement nonus businesses significantly direct customers information available direct customer product level inventory corresponding movement information reliability thirdparty demand information varies widely limit direct customer sales channel inventory reporting reliably gather report inventory levels customers number countries outside us contract distributors support certain products services provided distributors vary market may include distribution logistics regulatory pharmacovigilance andor sales advertising promotion sales distributorbased countries represented approximately companys total revenues competition markets compete generally broad based highly competitive compete worldwide researchbased drug companies many smaller research companies limited therapeutic focus generic drug manufacturers important competitive factors include product efficacy safety ease use price demonstrated costeffectiveness marketing effectiveness product labeling customer service rd new products processes sales products impacted new studies indicate competitors product safer effective treating disease particular form disease one products revenues also impacted additional labeling requirements relating safety convenience may imposed products fda similar regulatory agencies different countries competitors introduce new products processes therapeutic cost advantages products subject progressive price reductions decreased volume sales advancements treating cancer io therapies continue evolve rapid pace io products particularly opdivo operate highly competitive marketplace addition competing market share io products approved indications lung cancer melanoma face increased competition existing competing io products receive fda approval additional indications new io agents receive fda approval enter market furthermore therapies combining different io products io products existing chemotherapy targeted therapy treatments investigated potential expanded approvals anticipate io products continue experience intense competition another competitive challenge face generic pharmaceutical manufacturers us eu regulatory approval process exempts generics costly timeconsuming clinical studies demonstrate safety efficacy allowing generic manufacturers rely safety efficacy innovator product result generic pharmaceutical manufacturers typically invest far less rd researchbased pharmaceutical companies therefore price products significantly lower branded products accordingly branded product loses market exclusivity normally faces intense price competition generic forms product upon expiration loss market exclusivity product lose major portion product 's revenue short period time expiration exclusivity rate revenues decline product varies country general decline us market rapid developed countries though observed rapid declines number eu countries well also declines developed countries tend rapid developing countries rate revenues decline expiration exclusivity also historically influenced product characteristics example drugs used large patient population eg prescribed key primary care physicians tend experience rapid declines drugs specialized areas medicine eg oncology drugs complex manufacture eg sterile injectable products usually experience slower decline simpler manufacture certain countries outside us patent protection weak nonexistent must compete generic versions shortly launch innovative products addition generic pharmaceutical companies may introduce generic product exclusivity expired resolution related patent litigation information market exclusivity refer products intellectual property product exclusivity believe longterm competitive position depends upon success discovering developing innovative costeffective products serve unmet medical needs along ability manufacture products efficiently market effectively highly competitive environment pricing price constraints market access medicines priced based number factors including value scientific innovation patients society context overall health care spend economic factors impacting health care systems ability provide appropriate sustainable access necessity sustain investment innovation platforms address serious unmet medical needs central price clinical value innovation brings market current landscape alternative treatment options goal ensuring appropriate patient access innovation sustaining investment creative platforms continue explore new pricing approaches ensure patients access medicines enhancing patient access medicines priority us focused offering creative tiered pricing voluntary licensing reimbursement support patient assistance programs optimize access protecting innovation advocating sustainable healthcare policies infrastructure leveraging advocacypayers input utilizing partnerships appropriate improving access care supportive services vulnerable patients partnerships demonstration projects also monitoring new state laws laws recently enacted california vermont nevada new york focused drug pricing transparency andor limiting state spending drugs laws could create new constraints ability set prices andor impact market access certain states growth mcos optum uhc silver scripts cvs express scripts esi us also major factor healthcare marketplace half us population participates version managed care mcos include medical insurance companies medical plan administrators health maintenance organizations medicare part prescription drug plans alliances hospitals physicians physician organizations organizations consolidating fewer larger entities thus enhancing purchasing strength importance us successfully compete business mcos must often demonstrate products offer medical benefits also cost advantages compared forms care new products introduce compete products already market products later developed competitors noted generic drugs exempt costly timeconsuming clinical studies demonstrate safety efficacy often lower costs brandname drugs mcos focus primarily immediate cost drugs often favor generics reason many governments also encourage use generics alternatives brandname drugs healthcare programs laws us generally allow many cases require pharmacists substitute generic drugs rated government procedures essentially equivalent brandname drug substitution must made unless prescribing physician expressly forbids exclusion product formulary lead sharply reduced usage mco patient population consequently pharmaceutical companies compete aggressively products included possible companies compete inclusion based upon unique features products greater efficacy better patient ease use fewer side effects lower overall cost therapy also important factor products demonstrate fewer therapeutic advantages must compete inclusion based primarily price generally although universally successful major products included mco formularies many markets outside us operate environment governmentmandated costcontainment programs markets significant portion funding healthcare services determination pricing reimbursement pharmaceutical products subject government control result products may face restricted access public private payers may subject assessments comparative value effectiveness competitive products several governments placed restrictions physician prescription levels patient reimbursements emphasized greater use generic drugs andor enacted acrosstheboard price cuts methods cost control eu countries example government regulates pricing new product launch often direct price controls international price comparisons controlling profits andor reference pricing markets germany government set pricing restrictions launch pricing freedom subsequently limited companies may also face significant delays market access new products mainly france spain italy belgium year elapse new medicines become available national markets additionally member states eu regularly imposed new additional cost containment measures pharmaceuticals volume discounts cost caps cost sharing increases excess prior year costs individual products aggregated market level spending outcomebased pricing schemes free products portion expected therapy period recent years italy example imposed mandatory price decreases existence price differentials within eu due different national pricing reimbursement laws leads significant parallel trade flows government regulation pharmaceutical industry subject extensive global regulations regional country state local agencies federal food drug cosmetic act federal statutes regulations various state statutes regulations including newly enacted state laws regulating drug price transparency drug spending laws regulations foreign governments govern varying degrees testing approval production labeling distribution postmarket surveillance advertising dissemination information promotion products lengthy process laboratory clinical testing data analysis manufacturing development regulatory review necessary required governmental approvals extremely costly significantly delay product introductions given market promotion marketing manufacturing distribution pharmaceutical products extensively regulated major world markets addition operations subject complex federal state local foreign environmental occupational safety laws regulations anticipate laws regulations affecting manufacture sale current products introduction new products continue require substantial scientific technical effort time expense well significant capital investments fda particular importance us jurisdiction virtually activities imposes requirements covering testing safety effectiveness manufacturing labeling marketing advertising postmarketing surveillance products many cases fda requirements increased amount time money necessary develop new products bring market us fda mandates drugs manufactured packaged labeled conformity cgmp established fda complying cgmp regulations manufacturers must continue expend time money effort production recordkeeping quality control ensure products meet applicable specifications requirements ensure product safety efficacy fda periodically inspects drug manufacturing facilities ensure compliance applicable cgmp requirements failure comply statutory regulatory requirements subjects us possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experiences use products must reported fda could result imposition market restrictions labeling changes product removal product approvals may withdrawn compliance regulatory requirements maintained problems concerning safety efficacy occur following approval federal government extensive enforcement powers activities pharmaceutical manufacturers including authority withdraw delay product approvals commence actions seize prohibit sale unapproved noncomplying products halt manufacturing operations compliance cgmps impose seek injunctions voluntary recalls civil monetary criminal penalties restriction prohibition sales withdrawal approval products marketed us could materially adversely affect business financial condition results operations cash flows marketing authorization products subject revocation applicable governmental agencies addition modifications enhancements approved products changes manufacturing locations many circumstances subject additional fda approvals may may received may subject lengthy application process distribution pharmaceutical products subject pdma part federal food drug cosmetic act regulates activities federal state level pdma implementing regulations states permitted require registration manufacturers distributors provide pharmaceuticals even manufacturers distributors place business within state states also permitted adopt regulations limiting distribution product samples licensed practitioners pdma also imposes extensive licensing personnel recordkeeping packaging quantity labeling product handling facility storage security requirements intended prevent sale pharmaceutical product samples product diversions fda amendments act imposed additional obligations pharmaceutical companies delegated enforcement authority fda area drug safety key elements legislation give fda authority require companies conduct postmarketing safety studies drugs impose certain safety related drug labeling changes mandate risk mitigation measures education healthcare providers restricted distribution medicines require companies publicly disclose data clinical studies prereview television advertisements marketing practices us pharmaceutical manufacturers subject federal state healthcare laws used protect integrity government healthcare programs oig oversees compliance applicable federal laws connection payment products government funded programs primarily medicaid medicare laws include federal antikickback statute criminalizes offering something value induce recommendation order purchase products services reimbursed government healthcare program oig issued series guidances segments healthcare industry including compliance program guidance pharmaceutical manufacturers includes recommendation pharmaceutical manufacturers minimum adhere phrma code voluntary industry code marketing practices subscribe phrma code implemented compliance program address requirements set forth guidance compliance healthcare laws failure comply healthcare laws could subject us administrative legal proceedings including actions federal state government agencies actions could result imposition civil criminal sanctions may include fines penalties injunctive remedies impact could materially adversely affect business financial condition results operations cash flows also subject jurisdiction various federal state regulatory enforcement departments agencies federal trade commission department justice department health human services us also licensed us drug enforcement agency procure produce controlled substances therefore subject possible administrative legal proceedings actions organizations actions may result imposition civil criminal sanctions may include fines penalties injunctive administrative remedies us healthcare industry subject various governmentimposed regulations authorizing prices price controls continue impact total revenues participate state government medicaid programs well certain qualifying federal state government programs whereby discounts rebates provided participating state local government entities also participate government programs specify discounts certain government entities significant us department defense us department veterans affairs entities receive minimum discounts based defined nonfederal average manufacturer price purchases result patient protection affordable care act hr reconciliation bill containing package changes healthcare bill continue experience additional financial costs certain changes business example minimum rebates medicaid drug sales increased medicaid rebates also extended drugs used riskbased medicaid managed care plans addition extend discounts certain critical access hospitals cancer hospitals covered entities required expansion b drug pricing program public health service act required provide discount brandname drugs patients fall within medicare part coverage gap also referred donut hole pay annual nontaxdeductible fee federal government based allocation market share branded drug sales certain government programs including medicare medicaid department veterans affairs department defense tricare amount annual fee imposed pharmaceutical manufacturers whole billion fee billion decrease billion thereafter activities outside us also subject regulatory requirements governing testing approval safety effectiveness manufacturing labeling marketing products regulatory requirements vary country country whether fda ec approval obtained product approval product comparable regulatory authorities countries outside us eu case may must obtained prior marketing product countries approval process may less rigorous country country time required approval may longer shorter required us approval one country assure product approved another country discussion rebates programs refer item managements discussion analysis financial condition results operations gtn adjustments critical accounting policies sources availability raw materials general purchase raw materials supplies required production products open market products purchase raw materials supplies one source source available us single source approved source among many available us thereby requiring us obtain raw materials supplies particular source attempt possible mitigate raw material supply risks inventory management alternative sourcing strategies discussion sourcing refer manufacturing quality assurance discussions particular products manufacturing quality assurance operate manage manufacturing network manner permits us improve efficiency maintaining flexibility reallocate manufacturing capacity pharmaceutical production processes complex highly regulated vary widely product product given shifting adding manufacturing capacity lengthy process requiring significant capital expenditures well regulatory approvals maintain operate flexible manufacturing network consisting internal external resources minimize unnecessary product transfers inefficient uses manufacturing capacity discussion regulatory impact manufacturing refer government regulation price constraints significant pharmaceutical manufacturing facilities located us puerto rico france italy require significant ongoing capital investment maintenance compliance increasing regulatory requirements addition product portfolio changes next several years expect continue modification existing manufacturing network meet complex processing standards may required newly introduced products including biologics biologics manufacturing involves complex processes traditional pharmaceutical operations fda approved large scale multi product bulk biologics manufacturing facility devens massachusetts may continue make capital investments facility startup phase new largescale biologics manufacturing facility cruiserath ireland expected operational rely third parties manufacture supply us portion active product ingredient drug substance necessary us manufacture various products opdivo sprycel yervoy eliquis orencia baraclude reyataz sustiva franchise continue shift towards using third party manufactures supply established brands maintain stable supply products take variety actions including inventory management maintenance additional quantities materials possible designed provide reasonable level ingredients held thirdparty supplier us manufacturing operations interrupted certain supply arrangements extend multiple years minimum purchase obligations determined using expected near longterm demand requirements additional protection cases take steps maintain approved backup source available example capability manufacture opdivo internally also arrangements thirdparty manufacturers meet demand connection divestitures licensing arrangements distribution agreements certain products certain circumstances entered agreements agreed supply products third parties addition liabilities could arise failure supply products agreements arrangements could require us invest facilities production nonstrategic products result additional regulatory filings obligations cause interruption manufacturing products success depends great measure upon customer confidence quality products integrity data support safety effectiveness product quality arises total commitment quality parts operations including research development purchasing facilities planning manufacturing distribution maintain records demonstrate quality integrity technical information production processes control production processes involves established specifications standards ingredients equipment facilities manufacturing methods operations packaging materials labeling perform tests various stages production processes final product product samples held stability ensure product meets regulatory requirements conforms standards tests may involve chemical physical analyses microbiological testing combination along analyses quality control testing provided business unitsite thirdparty laboratories quality assurance groups routinely monitor manufacturing procedures systems used us subsidiaries thirdparty suppliers assure quality compliance requirements met environmental regulation facilities operations subject extensive us foreign laws regulations relating environmental protection human health safety including governing discharges pollutants air water use management disposal hazardous radioactive biological materials wastes cleanup contamination pollution controls permits required many operations permits subject modification renewal revocation issuing authorities environment health safety group monitors operations around world providing us overview regulatory requirements overseeing implementation standards compliance also incur operating capital costs matters ongoing basis material addition invested projects reduce resource use energy water although believe substantial compliance applicable environmental health safety requirements permits required operations nevertheless could incur additional costs including civil criminal fines penalties cleanup costs thirdparty claims property damage personal injury violations liabilities laws many current former facilities operation many years time operators facilities generated used stored disposed substances wastes considered hazardous federal state andor foreign environmental laws including cercla result soil groundwater certain facilities may contaminated may required make significant expenditures investigate control remediate contamination cases provide compensation andor restoration damages natural resources currently involved investigation remediation current former facilities also identified prp applicable laws environmental conditions approximately former waste disposal reprocessing facilities operated third parties investigation andor remediation activities ongoing may face liability cercla federal state foreign laws entire cost investigation remediation contaminated sites natural resource damages regardless fault ownership time disposal release addition certain sites bear remediation responsibility pursuant contractual obligations generally thirdparty operator sites involving multiple prps liability expected apportioned based nature amount hazardous substances disposed party site number financially viable prps additional information matters refer item financial statementsnote legal proceedings contingencies employees approximately employees december foreign operations significant operations outside us conducted subsidiaries distributors international operations subject certain risks inherent conducting business abroad including limited currency fluctuations possible nationalization expropriation price exchange controls counterfeit products limitations foreign participation local enterprises restrictive governmental actions international businesses also subject governmentimposed constraints including laws pricing reimbursement use products bristolmyers squibb website internet website address wwwbmscom website make available free charge annual quarterly current reports including amendments reports soon reasonably practicable electronically file material furnish material sec information relating corporate governance bristolmyers squibb including principles integrity code ethics senior financial officers code business conduct ethics directors collectively codes corporate governance guidelines information concerning executive committee board directors including board committees committee charters transactions bristolmyers squibb securities directors executive officers available website investorscorporate governance caption print stockholder upon request waivers codes directors executive officers material amendment code business conduct ethics directors code ethics senior financial officers posted promptly website information relating stockholder services including dividend reinvestment plan direct deposit dividends available website investorsstockholder services caption addition information sustainability programs available website responsibility caption incorporate reference certain information parts proxy statement annual meeting stockholders sec allows us disclose important information referring manner please refer information proxy statement annual meeting stockholders annual report available website investorssec filings caption march item risk factors factors described could significantly negatively affect business prospects financial condition operating results credit ratings could cause trading price common stock decline additional risks uncertainties presently known us risks currently consider immaterial could also impair operations financial condition public announcement data clinical studies competitors news developments related competitors ' io products latestage compounds may cause significant volatility stock price depending data may result adverse impact business financial condition results operation development key io compounds whether alone part combination therapy delayed discontinued clinical study meet one primary endpoints stock price could decline significantly may adverse impact business financial condition results operations focusing efforts resources disease areas high unmet need focused portfolio investors placing heightened scrutiny products latestage compounds particular opdivo backbone io portfolio announced multiple regulatory milestones opdivo including early stoppage certain clinical studies meeting endpoints label expansions new indications however also experienced setbacks may continue developments clinical studies expect receive data ongoing clinical studies including checkmate combination study firstline lung cancer setting decisions health authorities regarding potential label expansions announcement data clinical studies competitors news developments related competitors ' io products latestage compounds opdivo may cause significant volatility stock price depending news may result adverse impact business financial condition results operation furthermore announcement negative unexpected data discontinuation development key io compounds whether alone part combination therapy delay anticipated timelines filing regulatory approval significant advancement competitor may cause stock price decline significantly may adverse impact business financial condition results operations assurance data clinical studies support filings regulatory approval key io compounds may prove effective effective competing compounds even approved key io compounds become commercially successful approved indications depend several key products revenues cash flows earnings derive majority revenue earnings several key products six prioritized brands comprised approximately revenues growth products opdivo eliquis represented expected increasingly represent significant part revenue earnings cash flows reduction revenue products could adversely impact earnings cash flows also one major products become subject issues loss patent protection significant changes demand formulary access changes material product liability unexpected side effects regulatory proceedings negative publicity significant advancement competing products may incur adverse impact business financial condition results operation trading price stock may experience difficulties delays development commercialization new products compounds products may appear promising development fail reach market within expected optimal timeframe addition product extensions additional indications may approved furthermore products indications approved us fda 's accelerated approval program may contingent upon verification description clinical benefit confirmatory studies studies may successful example announced would pursue accelerated regulatory pathway combination opdivoyervoy lung cancer reported negative results checkmate experienced negative impacts stock price developing commercializing new compounds products include inherent risks uncertainties including due efficacy safety concerns delayed denied regulatory approvals delays challenges producing products commercial scale excessive costs manufacture ii failure enter implement optimal alliances development andor commercialization new products iii failure maintain consistent scope variety promising latestage products iv failure one products achieve maintain commercial viability v changes regulatory approval processes may cause delays denials new product approvals regulatory approval delays especially common product expected risk evaluation mitigation strategy required fda address significant riskbenefit issues inability bring product market significant delay expected approval related launch date new product could negatively impact revenues earnings addition certain acquired pipeline programs canceled believe commercial prospects reduced may recognize material noncash impairment charges programs finally losing key molecules intermediaries compound library natural manmade disaster act sabotage could negatively impact product development cycle face intense competition manufacturers including innovative medicines lowerpriced generic products bms dependent market access uptake expansion marketed brands new product introductions new indications product extensions co promotional activities alliance partners deliver future growth competition keen includes lowerpriced generics increasingly aggressive generic commercialization tactics ii new competitive products entering market particularly io iii lower prices companies ' products real perceived superior efficacy benefit safety risk profiles differentiating factors iv technological advances patents attained competitors v clinical study results products competitors products affect value proposition products vi business combinations among competitors major thirdparty payers vii competing interests external partnerships develop bring new products markets unable compete successfully competitors ' products marketplace could material negative impact revenues earnings litigation claiming infringement intellectual property may adversely affect future revenues operating earnings third parties may claim infringe upon intellectual property resolving intellectual property infringement claim costly time consuming may require us enter license agreements may available commercially reasonable terms successful claim patent intellectual property infringement could subject us significant damages injunction preventing manufacture sale use affected product products events could material adverse effect profitability financial condition adverse outcomes legal matters could negatively affect business current future lawsuits claims proceedings government investigations could preclude delay commercialization products could adversely affect operations profitability liquidity financial condition possible insurance recoveries available legal matters include intellectual property disputes ii adverse decisions litigation including product liability commercial cases iii antibribery regulations us foreign corrupt practice act uk bribery act including compliance ongoing reporting obligations government resulting settlements iv recalls withdrawals pharmaceutical products forced closings manufacturing plants v failure fulfill obligations supply contracts government customers vi product pricing promotional matters vii lawsuits claims asserting investigations violations securities antitrust federal state pricing consumer protection data privacy laws viii environmental health safety sustainability matters ix tax liabilities resulting assessments tax authorities could lose market exclusivity product earlier expected pharmaceutical biotechnology industries majority innovative products commercial value realized market exclusivity period us countries market exclusivity expires generic versions approved marketed biosimilars introduced even competing product usually substantial rapid declines products revenues market exclusivity products based upon patent rights certain regulatory forms exclusivity scope patent rights varies country country may also dependent availability meaningful legal remedies country failure obtain patent intellectual property rights limitations use loss rights could material us countries including certain eu member states basic patent protections products may exist certain countries historically offer right obtain specific types patents andor licensors file countries addition patent environment unpredictable validity enforceability patents predicted certainty absent relevant patent protection product data exclusivity period expires generic versions approved marketed generic biosimilar product manufacturers well groups seeking financial gain also increasingly seeking challenge patents expire could face earlierthanexpected competition products time patents covering key products likely continue subject patent litigation example february one eu patents sprycel revoked opposition division epo may experience decline european revenues upon entry generics market refer item financial statementsnote legal proceedings contingencies information cases manufacturers may seek regulatory approval submitting clinical study data obtain marketing approval choose launch generic product risk expiration applicable patents andor final resolution related patent litigation assurance particular product enjoy market exclusivity full time period appears estimates disclosed assume provide financial guidance addition countries india allowing competitors manufacture sell competing generic products negatively impacts protections afforded company lowerpriced biosimilars bms biologic products competing biologics could negatively impact volumes prices increased pricing pressure restrictions us abroad mcos institutional purchasers government agencies programs among others could negatively affect revenues profit margins products continue subject increasing pressures across portfolio market access pricing discounting restrictions us eu regions around world including rules practices mcos institutional governmental purchasers ii judicial decisions changes laws regulations federal healthcare programs medicare medicaid government actions inquiries federal state level laws recently enacted california vermont nevada new york focused drug pricing transparency andor limiting state spending drugs iii potential impact changes pharmaceutical reimbursement increased pricing pressure medicare part formularies medicare part b reimbursement rates physicians well commercial formularies general iv reimbursement delays v government price erosion mechanisms across europe countries resulting deflation pharmaceutical product pricing vi collection delays failures pay governmentfunded public hospitals outside us vii impact pricing parallel trade across borders viii developments technology andor industry practices could impact reimbursement policies practices thirdparty payers ix inhibited market access due real perceived differences value propositions products compared competing products subject variety us international laws regulations currently subject number government laws regulations future could become subject new government laws regulations costs compliance laws regulations negative results noncompliance could adversely affect business operating results financial condition company include additional healthcare reform initiatives us countries including additional mandatory discounts fees ii new laws regulations judicial governmental decisions affecting pricing drug reimbursement receivable payments access marketing within across jurisdictions iii changes intellectual property law iv changes accounting standards v new increasing data privacy regulations enforcement particularly european union us vi emerging new global regulatory requirements reporting payments value transfers healthcare professionals vii potential impact importation restrictions legislative andor regulatory changes changes tax regulations could negatively impact earnings subject income taxes us various countries globally particular although passage tax cut jobs act reduced us tax rate future earnings could negatively impacted changes tax legislation including changing tax rates tax base limiting phasingout eliminating deductions tax credits taxing certain excess income intellectual property changing rules earnings repatriations changing tax laws us countries addition onetime deemed repatriation tax approximately billion payable next eight years thirdparty royalties represent significant percentage pretax income operating cash flow entered several arrangements entitle us potential royalties third parties outlicensed intellectual property commercialization rights salesbased contingent proceeds related divestiture businesses many arrangements minimal continuing involvement contribute financial success activities royalties continued represent significant percentage pretax income including royalties related divestiture erbitux diabetes businesses including transfer certain future royalty rights pertaining amylin onglyza farxiga product sales sanofi alliance outlicensed intellectual property merck patent infringement settlement pretax income generated royalties approximately billion expected increase pretax income could adversely affected royalty streams decline future periods failure third parties meet contractual regulatory obligations could adversely affect business rely suppliers vendors outsourcing partners alliance partners third parties research develop manufacture commercialize copromote sell products manage certain marketing selling human resource finance business unit functional services meet contractual regulatory obligations using third parties poses number risks may perform standards legal requirements example relation outsourcing significant clinical development activities innovative medicines contract research organizations ii may produce reliable results iii may perform timely manner iv may maintain confidentiality proprietary information v may incur significant cyberattack business disruption vi disputes may arise respect ownership rights technology developed partners vii disagreements could cause delays termination research development commercialization product result litigation arbitration moreover third parties located markets subject political social risk corruption infrastructure problems natural disasters addition country specific privacy data security risk given current legal regulatory environments failure critical third party meet obligations including future royalty milestone payments adequately deploy business continuity plans event crisis andor satisfactorily resolve significant disagreements us address factors could material adverse impact operations results addition third parties violate alleged violated laws regulations including local pharmaceutical code us foreign corrupt practice act uk bribery act similar laws regulations performance obligations us possible could suffer financial reputational harm negative outcomes including possible legal consequences failure execute business strategy could adversely impact growth profitability strategy focused delivering innovative transformational medicines patients unable successfully execute strategy could negatively impact future results operations market capitalization connection strategy process evolving operating model focus investment commercial opportunities key brands markets accelerate pipeline streamline operations realign manufacturing capabilities broaden biologics capabilities among things ability successfully execute operating model evolution could impact results able achieve cost savings expect could negatively impact operating margin earnings results addition may unable consistently maintain adequate pipeline internal rd programs transactions third parties support future revenue growth competition among pharmaceutical companies acquisition product licensing opportunities intense may able locate suitable acquisition targets licensing partners reasonable prices successfully execute transactions unable support grow marketed products successfully execute launches newly approved products advance latestage pipeline manage change operating model evolution manage costs effectively operating results financial condition could negatively impacted failure attract retain highly qualified personnel could affect ability successfully develop commercialize products success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical rd governmental regulation commercialization competition qualified personnel biopharmaceutical field intense sure able attract retain quality personnel costs materially increase businesses assets acquire future may underperform may able successfully integrate existing business essential component strategy business development activities seeking source innovation externally supplement discovery development efforts acquired inlicensed number assets expect continue support pipeline compounds products obtained licensing acquisitions future revenues profits cash flows acquired companys products technologies pipeline candidates may materialize due low product uptake delayed missed pipeline opportunities inability capture expected synergies increased competition safety concerns regulatory issues supply chain problems factors beyond control example discontinued development fs phase development treatment breast gastric cancer consequently exercise option purchase fstar alpha result recorded iprd charge million substantial difficulties costs delays could result integrating acquisitions including rd manufacturing distribution sales marketing promotion information technology activities ii policies procedures processes controls compliance iii tax considerations could experience difficulties delays manufacturing distribution sale products product supply related patient access could negatively impacted among things product seizures recalls forced closings manufacturing plants ii failure failure suppliers comply cgmp applicable regulations quality assurance guidelines could lead manufacturing shutdowns product shortages delays product manufacturing iii manufacturing quality assurancequality control supply problems governmental approval delays iv failure sole source single source supplier provide us necessary raw materials supplies finished goods within reasonable timeframe required quality v failure thirdparty manufacturer supply us bulk active finished product time vi construction regulatory approval delays new facilities expansion existing facilities including intended support future demand biologics products opdivo vii failure meet new emerging regulations requiring products tracked throughout distribution channels using unique identifiers verify authenticity supply chain viii manufacturing distribution issues including limits manufacturing capacity changes types products produced biologics physical limitations business interruptions ix disruption supply chain continuity including natural disasters acts war terrorism external factors control impacting one facilities critical supplier example new biologics manufacturing facility cruiserath ireland expected operational delay planned opening site could impact supply products require us obtain product supply third parties significant cost manufacturing commercial operations puerto rico impacted recent hurricanes two manufacturing sites sustained damage currently operating reduced capacity continue work restore normal operations disruption ability operate puerto rico manufacturing facilities whether due problems facility infrastructure services available island unavailability raw materials supplies vendors unavailability key staff otherwise could materially adversely affect ability supply products affect product sales product labeling changes marketed products could result negative impact revenues profit margins regulatory authorities may need change labeling pharmaceutical product including product marketed several years changes often result additional data postmarketing studies headtohead studies adverse events reports studies identify biomarkers objective characteristics indicate particular response product therapy studies postmarketing experience produce important additional information product new information added products label affect riskbenefit profile leading potential recalls withdrawals declining revenue well product liability claims sometimes additional information studies identifies portion patient population may nonresponsive medicine would higher risk adverse reactions labeling changes based studies may limit patient population studies providing additional information may sponsored us could also sponsored competitors insurance companies government institutions managed care organizations scientists investigators interested parties additional safety efficacy information studies assist us healthcare providers identifying best patient population product also negatively impact revenues due inventory returns limited patient population going forward additionally certain study results especially headtohead studies could affect products formulary listing could also adversely affect revenues illegal distribution sale third parties counterfeit unregistered versions products stolen products could negative impact revenues earnings reputation business third parties may illegally distribute sell counterfeit versions products meet rigorous manufacturing testing standards patient receives counterfeit drug may risk number dangerous health consequences reputation business could suffer harm result counterfeit drugs sold brand name thefts inventory warehouses plants intransit properly stored later sold unauthorized channels could adversely impact patient safety reputation business addition diversion products authorized market channels may result reduced revenues negatively affect profitability dependent information technology systems infrastructure face certain risks including cybersecurity breaches data leakage rely extensively systems networks services including internet sites data hosting processing facilities tools physical security systems hardware software technical applications platforms managed hosted provided andor used thirdparties vendors assist conducting business significant breakdown invasion corruption destruction interruption critical information technology systems infrastructure workforce others authorized access systems unauthorized persons could negatively impact operations everincreasing use evolution technology including cloudbased computing creates opportunities unintentional dissemination intentional destruction confidential information stored thirdparty providers ' systems portable media storage devices could also experience business interruption theft confidential information reputational damage industrial espionage attacks malware cyberattacks may compromise system infrastructure lead data leakage either internally thirdparty providers although aggregate impact operations financial condition material date target events nature expect continue cybersecurity threats rapidly evolving sophistication becoming prevalent industry invested industry appropriate protections monitoring practices data reduce risks continue monitor systems ongoing basis current potential threats maintain cyber insurance however insurance may sufficient cover financial legal business reputational losses may result interruption breach systems assurance continuing efforts prevent breakdowns breaches thirdparty providers databases systems could adversely affect business adverse changes us global regional local economic political conditions could adversely affect profitability global economic political risks pose significant challenges companys growth profitability difficult mitigate generated approximately revenues outside us revenues earnings cash flow exposed risk strengthening us dollar exposure customer credit risks europe south america markets including governmentguaranteed hospital receivables markets payments received time significant operations europe including manufacturing distribution results operations could negatively impacted member country exiting eurozone monetary union eu including planned exit uk eu note exit uk eu may impact research commercial general business operations uk eu addition future pension plan funding requirements continue sensitive global economic conditions related impact equity markets additionally disruptions credit markets downgrade current credit rating could increase future borrowing costs impair ability access capital credit markets terms commercially acceptable us could adversely affect liquidity capital resources significantly increase cost capital finally business operations may adversely affected political volatility conflicts crises individual countries regions including terrorist activities war guarantee pay dividends repurchase stock declaration amount timing dividends fall within discretion board directors board 's decision depend many factors including financial condition earnings capital requirements debt service obligations industry practice legal requirements regulatory constraints factors board directors may deem relevant reduction elimination dividend payments dividend program could adversely affect stock price addition could time decide buy back shares market could also adversely affect stock price increased use social media platforms present risks challenges increasing use social media communicate company news events inappropriate andor unauthorized use certain media vehicles could cause brand damage information leakage could lead legal implications including improper collection andor dissemination personally identifiable information employees patients healthcare professionals stakeholders addition negative inaccurate posts comments us social networking website could damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce others external media channels could lead information loss identifying new points entry social media continues expand presents new challenges item b unresolved staff comments none item properties principal executive offices located park avenue new york ny lease manufacturing rd administration storage distribution facilities approximately sites worldwide believe manufacturing properties combination thirdparty manufacturers provide adequate production capacity current operations information manufacturing properties refer item businessmanufacturing quality assurance significant manufacturing rd locations geographic area follows december manufacturing rd united states europe total item legal proceedings information pertaining legal proceedings found item financial statementsnote legal proceedings contingencies incorporated reference herein item mine safety disclosures applicable part ia executive officers registrant listed information executive officers february executive officers elected board directors initial term continues first board meeting following next annual meeting stockholders thereafter elected oneyear term successors elected executive officers serve discretion board directors name current position age employment history past years giovanni caforio md president us pharmaceuticals chairman board chief executive officer executive vice president chief commercial officer member leadership team chief operating officer director company chief executive officer director company present chairman board chief executive officer charles bancroft chief financial officer executive vice president global services chief financial officer executive vice president present chief financial officer executive vice president global business global business operations operations member leadership team joseph c caldarella present senior vice president corporate controller senior vice president corporate controller john e elicker senior vice president public affairs investor relations senior vice president corporate affairs investor present senior vice president corporate affairs investor relations relations member leadership team murdo gordon senior vice president oncology immunology executive vice president chief commercial officer president us pharmaceuticals member leadership team senior vice president head worldwide markets present executive vice president chief commercial officer ann powell judge chief human resources officer shire pharmaceuticals senior vice president chief human resources senior vice president global human resources officer present senior vice president chief human resources officer member leadership team sandra leung general counsel corporate secretary executive vice president general counsel executive vice president general counsel corporate secretary member leadership team present executive vice president general counsel thomas j lynch md present executive vice president chief scientific officer executive vice president chief scientific officer member leadership team louis schmukler president global product development supply senior vice president president global product present senior vice president president global product development supply development supply member leadership team paul von autenried senior vice president enterprise services chief information officer senior vice president chief information officer present senior vice president chief information officer member leadership team part ii item market registrants common stock stockholder matters market prices bristolmyers squibb common stock traded new york stock exchange symbol bmy quarterly summary high low closing market price presented high low high low common first quarter second quarter third quarter fourth quarter holders common stock number record holders common stock december number record holders based upon actual number holders registered books date include holders shares street names persons partnerships associations corporations entities identified security position listings maintained depository trust companies dividends board directors declared following quarterly dividends per share paid periods indicated common preferred first quarter second quarter third quarter fourth quarter december board directors declared quarterly dividend per share common stock paid february shareholders record january board directors also declared quarterly dividend per share preferred stock payable march shareholders record february unregistered sales equity securities use proceeds following table summarizes surrenders equity securities three months ended december total number shares approximate dollar value average price purchased part shares may yet total number paid publicly announced purchased period shares purchaseda per sharea programsb programsb dollars millions except per share data october november december three months ended december includes shares repurchased part publicly announced programs shares common stock surrendered company satisfy tax withholding obligations connection vesting awards longterm incentive program b may board directors authorized repurchase billion common stock june increased authorization repurchase common stock additional billion october board directors approved new share repurchase program authorizing repurchase additional billion common stock stock repurchase program expiration date item selected financial data five year financial summary amounts millions except per share data income statement dataa total revenues net earnings net earningsloss attributable noncontrolling interest bms net earnings per common share attributable bms basic diluted average common shares outstanding basic diluted cash dividends paid bms common preferred stock cash dividends declared per common share financial position data december cash cash equivalents marketable securitiesb total assets longterm debtb equity discussion items affected comparability results years refer item managements discussion analysis financial condition results operationsnongaap financial measures b includes current noncurrent portion item managements discussion analysis financial condition results operations executive summary bristolmyers squibb company global specialty biopharmaceutical company whose mission discover develop deliver innovative medicines help patients prevail serious diseases refer summary abbreviated terms end terms used throughout document received approvals new medicines additional indications formulations currently marketed medicines major markets us eu japan china including multiple regulatory milestone achievements opdivo committed investigating opdivo alone combination yervoy anticancer agents wide array tumor types including broad programs lung head neck liver kidney bladder gastric continue believe breadth depth io portfolio positions us well future new io compounds clinical development studies across different tumor types addition advanced certain nonio rd programs pipeline including fgf treatment nash tyk inhibitor treatment immune diseases psoriasis also continued progress company transformation initiatives enabling us invest highest priority portfolio opportunities revenues increased result higher demand prioritized brands including opdivo eliquis partially offset increased competition established brands primarily daklinza decrease gaap eps due tax charges attributed tax reform per share lesser extent higher license asset acquisition restructuring related charges lower divestiture related income items partially offset higher revenues royalties licensing income patentinfringement settlement adjusting impact tax reform specified items nongaap eps increased primarily result higher revenues partially offset product mix higher rd expenses supporting opdivo io programs revenues increased result higher demand prioritized brands including opdivo eliquis partially offset expiration us commercialization rights abilify transfer erbitux rights north america increased competition reyataz sustiva baraclude certain markets increase gaap eps due higher revenues divestiturerelated income lower license asset acquisition charges partially offset higher opdivo related expenses adjusting impact divestiture gains rd license asset acquisition charges specified items nongaap eps increased primarily result higher revenues partially offset product mix highlights following table summarizes financial information year ended december dollars millions except per share data total revenues diluted earnings per share gaap nongaap nongaap financial measures including nongaap earnings related eps information adjusted exclude specified items represent certain costs expenses gains losses items impacting comparability financial results detailed listing specified items information reconciliations nongaap financial measures refer nongaap financial measures significant product pipeline approvals following summary significant approvals received product date approval fda approval injection intravenous use adjuvant treatment patients melanoma december involvement lymph nodes metastatic disease undergone complete resection fda approval treatment patients hcc type liver cancer previously treated sorafenib september approval japan treatment unresectable advanced recurrent gastric cancer progressed chemotherapy received alliance partner ono fda approval treatment adult pediatric patients msih dmmr mcrc opdivo august progressed following treatment fluoropyrimidine oxaliplatin irinotecan ec approval treatment patients previously treated locally advanced unresectable metastatic june urothelial carcinoma type bladder cancer adults failure platinumcontaining therapy april ec approval treatment scchn adults progressing platinumbased therapy march approval japan treatment recurrent metastatic hnc received alliance partner ono fda approval treatment patients previously treated locally advanced metastatic urothelial february carcinoma ec approval treatment active psa adults response previous diseasemodifying antirheumatic drug therapy including methotrexate inadequate additional systemic therapy july psoriatic skin lesions required orencia fda approval treatment active psa adults fda approval new subcutaneous administration option use patients two years age older march moderately severely active polyarticular jia fda expanded indication sprycel tablets include treatment children philadelphia sprycel november chromosomepositive cml chronic phase fda approval expanded indication treatment unresectable metastatic melanoma pediatric yervoy july patients china fda approval daklinza sunvepra regimen treatmentnaive experienced patients hepatitis c franchise april infected genotype b chronic hcv addition daklinza approved china combination use agents including sofosbuvir adult patients hcv genotypes infection refer product pipeline developments developments marketed products latestage pipeline early strategy focus specialty biopharmaceutical company discovering developing delivering transformational medicines address serious unmet medical needs strategy combine resources scale capability pharmaceutical company speed focus innovation biotech industry four strategic priorities drive business performance continue build leading franchise io maintain diversified portfolio within outside io continue disciplined approach capital allocation including establishing partnerships collaborations inlicensing acquiring investigational compounds essential component successfully delivering transformational medicines patients developing new medicines following core therapeutic areas oncology priority io immunoscience priorities lupus rheumatoid arthritis inflammatory bowel disease cardiovascular priority heart disease fibrotic disease priorities lung liver continue advance next wave innovative medicines investing significantly pipeline internally business developments activities io continue invest monotherapy studies combination approaches next wave early assets entered several collaboration agreements expanded others research develop opdivo approved investigational oncology agents combination regimens remain focused well resourced cancer development programs seek broaden use opdivo earlier lines therapy expand new tumors accelerate next wave io mechanisms develop treatment options refractory io patients beyond cancer continue advance early stage portfolio immunoscience cardiovascular fibrotic diseases strengthen partnerships diverse group companies academic institutions new expanded research activities believe differentiated internal external focus contributes advancing pipeline potentially transformational medicines commercial model evolving revenues marketed product portfolio continue grow demonstrates strong execution strategy continue drive growth opdivo expanding additional indications tumor types monotherapy combination yervoy anticancer agents eliquis continues grow leveraging best class clinical profile extensive real world data number one novel oral anticoagulant total prescriptions us building continued success prioritized brands remain strongly committed orencia sprycel operating model transformation commercial infrastructure uniquely leveraged potential growth operating model continues evolve successful focusing commercial rd resources prioritized brands markets strengthening rd capabilities tumor biology patient selection new biomarkers delivering leaner administrative functions streamlining manufacturing network reflect importance biologics current future portfolio evolution operating model enable us deliver necessary strategic financial operational flexibility invest highest priority opportunities within portfolio looking ahead continue implement biopharma strategy driving growth key brands executing product launches investing diverse innovative pipeline aided strategic business development focusing prioritized markets increasing investments biologics manufacturing capabilities maintaining culture continuous improvement acquisition licensing arrangements acquisition licensing arrangements allow us focus resources behind growth opportunities drive greatest longterm value focused following core therapeutic areas oncology including io immunoscience cardiovascular fibrosis significant arrangements past three years summarized refer item financial statementsnote acquisitions divestitures licensing arrangements information arrangements ono bms acquired exclusive license develop commercialize ono onos prostaglandin e receptor antagonist treatment cancer bms acquired worldwide rights except japan south korea taiwan added existing collaboration china asean countries ono retained exclusive rights halozyme bms halozyme entered global collaboration license agreement develop subcutaneously administered bms io medicines using halozyme 's enhanze drugdelivery technology may allow rapid delivery large volume injectable medications ifm bms acquired outstanding shares ifm providing bms full rights ifm 's preclinical sting nlrp agonist programs focused enhancing innate immune response treating cancer biogen bms outlicensed biogen exclusive rights develop commercialize bms antietau compound development progressive supranuclear palsy roche bms outlicensed roche exclusive rights develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy cytomx bms cytomx expanded initial strategic collaboration discover novel cancer treatment therapies include eight additional targets using cytomxs proprietary probody platform treatment cancer arrangements psioxus bms acquired exclusive worldwide rights psioxus 's ng preclinical stage armed oncolytic virus goal addressing solid tumors padlock bms acquired outstanding shares padlock providing bms full rights padlocks pad inhibitor discovery program focused development treatment approaches patients rheumatoid arthritis cormorant bms acquired outstanding shares cormorant providing bms full rights cormorant 's lead candidate humaxil monoclonal antibody represents potentially complementary io mechanism action tcell directed antibodies costimulatory molecules nitto denko bms acquired exclusive worldwide license develop commercialize nitto denko 's investigational sirna molecules targeting heat shock protein hsp vitamin containing formulations including nitto denko 's lead asset ndls currently development treatment advanced liver fibrosis option receive exclusive licenses hsp sirnas vitamin containing formulations treatment lung organ fibrosis arrangements flexus bms acquired outstanding shares flexus providing bms full rights f preclinical small molecule idoinhibitor targeted immunotherapy potential used combination bms 's immunooncology portfolio addition transaction included flexus 's idotdo discovery program included idoselective idotdo dual tdoselective compounds cardioxyl bms acquired outstanding shares cardioxyl providing bms full rights cxl nitroxyl prodrug development acute decompensated heart failure five prime bms five prime entered exclusive worldwide licensing collaboration agreement develop commercialize five primes csfr antibody program including cabiralizumab currently development io indications pvns bms responsible development manufacturing commercialization cabiralizumab subject five primes option conduct certain studies cost develop cabiralizumab pvns combination internal oncology pipeline assets promedior bms acquired warrant providing bms exclusive rights acquire promedior whose lead asset prm developed treatment ipf mf warrant exercisable upon provided data following completion either ipf mf phase ii clinical studies directed promedior bavarian nordic bms acquired exclusive option globally license commercialize prostvac bavarian nordics investigational phase iii prostatespecific antigentargeting cancer immunotherapy development treatment asymptomatic minimally symptomatic metastatic castrationresistant prostate cancer independent data monitoring committee determined continuation phase iii prospect study prostvac patients metastatic castrationresistant prostate cancer futile uniqure bms entered collaboration license agreement uniqure granting bms exclusive license uniqures gene therapy technology platform specific collaboration targets collaboration includes uniqures proprietary gene therapy program congestive heart failure intended restore hearts ability synthesize sa calcium sensor master regulator heart function thereby improve clinical outcomes patients reduced ejection fraction results operations regional revenues composition changes revenues follows year ended december vs vs total revenues analysis change analysis change total foreign total foreign dollars millions change exchangeb change exchangeb united states europe rest world othera na na total revenues include royalties alliancerelated revenues products sold regional commercial organizations b foreign exchange impacts derived applying prior period average currency rates current period sales us revenues increased due higher demand eliquis opdivo partially offset lower demand established brands due increased competition primarily daklinza hiv brands lower growth rate us due additional competition opdivo daklinza average us net selling prices approximately higher chargebacks rebates discounts refer product revenues commentary additional information us revenues increased due higher demand opdivo eliquis daklinza partially offset full year impact expirationtransfer commercialization rights abilify erbitux average us net selling prices approximately higher chargebacks rebates discounts europe revenues increased due higher demand opdivo eliquis partially offset lower demand daklinza due increased competition europe revenues increased due higher demand opdivo eliquis partially offset lower demand yervoy rest world revenues decreased due lower demand established brands including daklinza due increased competition outlicensing mature brand product partially offset higher demand opdivo eliquis rest world revenues decreased due increased competition hepatitis c franchise japan unfavorable foreign exchange primarily latin america partially offset higher demand opdivo eliquis revenues decreased result expiration certain supply arrangements refer item financial statementsnote alliances discussion alliances single country outside us contributed total revenues except japan contributed total revenues gtn adjustments recognize revenue net gtn adjustments described critical accounting policies share certain abilify atripla revenues reflected net gtn adjustments alliance revenues activities ending reserve balances significant category gtn adjustments follows rebates chargebacks medicaid medicare returns discounts dollars millions cash discounts rebates adjustments total balance january provision related sale made current period prior period payments returns foreign currency translation balance december provision related sale made current period prior period payments returns foreign currency translation balance december reconciliation gross product sales net product sales significant category gtn adjustments follows excluding alliance revenues abilify atripla year ended december change dollars millions vs vs gross product sales gtn adjustments chargebacks cash discounts medicaid medicare rebates rebates returns discounts adjustments total gtn adjustments net product sales gtn adjustments percentage us nonus gtn adjustments primarily function product sales volume regional payer channel mix contractual legislative discounts rebates gtn adjustments increasing higher rate gross product sales due higher us eliquis gross product sales relatively high gtn adjustment percentage result competitive pressures maintain position healthcare payer formularies allowing patients continued access medical plans product revenues year ended december change dollars millions vs vs prioritized brands opdivo us nonus eliquis us nonus orencia us nonus sprycel us nonus yervoy us nonus empliciti us nonus na established brands baraclude us nonus sustiva franchise us nonus reyataz franchise us nonus hepatitis c franchise us nonus brands us nonus total revenues us nonus change excess opdivo nivolumab fully human monoclonal antibody binds pd nkt cells approved several anticancer indications including bladder blood colon head neck kidney liver lung melanoma stomach continues investigated across tumor types disease areas us revenues increased periods due higher demand expect increased competition opdivo continue future due new product entrants expanded indications international revenues increased periods due higher demand result launches additional indications approvals new countries eliquis apixaban oral factor xa inhibitor targeted stroke prevention adult patients nonvalvular atrial fibrillation prevention treatment vte disorders us international revenues increased periods due higher demand resulting increased commercial acceptance novel oral anticoagulants market share gains orencia abatacept fusion protein indicated adult patients moderate severe active ra psa also indicated reducing signs symptoms certain pediatric patients moderately severely active polyarticular juvenile idiopathic arthritis us revenues increased periods due higher average net selling prices demand international revenues increased periods due higher demand sprycel dasatinib oral inhibitor multiple tyrosine kinase indicated firstline treatment adults philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adults chronic accelerated myeloid lymphoid blast phase cml resistance intolerance prior therapy including gleevec imatinib meslylate us revenues increased periods due higher demand average net selling prices international revenues increased periods due higher demand may experience decline european revenues event generic datasinib product enters market yervoy ipilimumab monoclonal antibody treatment patients unresectable metastatic melanoma us revenues increased periods primarily due higher demand international revenues increased due higher demand europe following approval opdivoyervoy combination therapy melanoma international revenues decreased due lower demand resulting introduction io products used treat patients melanoma including opdivo empliciti elotuzumab humanized monoclonal antibody treatment multiple myeloma empliciti launched us december eu may japan september baraclude entecavir oral antiviral agent treatment chronic hepatitis b international revenues continued decrease periods due lower demand resulting increased competition sustiva efavirenz franchise nonnucleoside reverse transcriptase inhibitor treatment hiv includes sustiva antiretroviral drug bulk efavirenz also included combination therapy atripla us revenues continued decrease periods due lower demand resulting increased competition new product entrants decrease partially offset higher average net selling prices loe occurred december gilead terminated bms 's participation us canada joint venture following launch generic version sustiva us result bms 's share atripla revenues decline next three years refer item financial statementsnote alliances discussion reyataz atazanavir sulfate franchise includes reyataz protease inhibitor treatment hiv evotaz atazanavir mg cobicistat mg combination therapy containing reyataz tybost cobicistat us revenues continued decrease due lower demand resulting new product entrants decrease partially offset higher average net selling prices loe occurred december result higher decline revenues future periods due generic competition international revenues continued decrease periods due lower demand resulting increased competition decrease also impacted unfavorable foreign exchange hepatitis c franchise daklinza daclatasvir nsa replication complex inhibitor sunvepra asunaprevir ns protease inhibitor beclabuvir nsb inhibitor us revenues decreased due lower demand resulting new product entrants us revenues increased due launch daklinza july international revenues decreased periods due lower demand resulting increased competition due new product entrants brands includes brands including lost exclusivity major markets otc brands royalty revenue us revenues decreased due expiration bms 's commercialization rights abilify april transfer bms 's north american erbitux rights lilly october refer item financial statementsnote alliances discussion international revenues decreased due outlicensing divestiture certain brands continued generic erosion international revenues decreased due expiration certain supply arrangements divestiture certain brands increased competition otc brands unfavorable foreign exchange estimated enduser demand pursuant sec consent order described sec consent order monitor level inventory hand us wholesaler distribution channel outside us direct customer distribution channel obligated disclose products levels inventory excess one month hand expected demand subject de minimis exception estimated levels inventory distribution channel excess one month hand following products material results operations dates indicated december daklinza months inventory hand us result minimum required stock levels support patient demand expect inventory hand levels daklinza exceed one month near term international products estimated levels inventory distribution channel excess one month hand september dafalgan analgesic product sold principally europe months inventory hand internationally direct customers compared also months inventory hand june level inventory hand primarily attributable france support product seasonality efferalgan analgesic product sold principally europe months inventory hand internationally direct customers compared months inventory hand june level inventory hand primarily attributable france support product seasonality fervex cold flu product months inventory hand direct customers compared months inventory hand june level inventory hand attributable france support product seasonality perfalgan analgesic product months inventory hand internationally direct customers compared months inventory hand june level inventory hand primarily gulf countries due extended delivery lead time us generally determine months hand estimates using inventory levels product hand amount outmovement provided three largest wholesalers account approximately total gross sales us products factors may influence estimates include generic competition seasonality products wholesaler purchases light increases wholesaler list prices new product launches new warehouse openings wholesalers new customer stockings wholesalers addition estimates calculated using thirdparty data may impacted recordkeeping processes nonus businesses significantly direct customers information available direct customer product level inventory corresponding movement information reliability thirdparty demand information varies widely limit direct customer sales channel inventory reporting influence demand information exist otherwise available developed variety methodologies estimate data including using historical sales made direct customers thirdparty market research data related prescription trends enduser demand given difficulties inherent estimating thirdparty demand information evaluate methodologies estimate direct customer product level inventory calculate months hand ongoing basis make changes necessary factors may affect estimates include generic competition seasonality products price increases new product launches new warehouse openings direct customers new customer stockings direct customers expected direct customer purchases governmental bidding situations information required estimate months hand direct customer distribution channel nonus business year ended december available prior filing annual report disclose product levels inventory excess one month hand expected demand subject de minimis exception next quarterly report form q expenses change dollar millions vs vs cost products sold marketing selling administrative research development income net total expenses change excess cost products sold cost products sold include material internal labor overhead costs owned manufacturing sites thirdparty product supply costs supply chain costs managed global manufacturing supply organization cost products sold also includes royalties profit sharing certain excise taxes foreign currency hedge settlement gains losses amortization acquired developed technology costs cost products sold typically vary periods result product mix volume particularly royalties profit sharing lesser extent changes foreign currency price inflation costs attributed manufacturing site exits cost products sold increased due higher eliquis profit sharing million million impairment charge reduce carrying value small molecule active pharmaceutical ingredient manufacturing operations swords ireland remaining increase primarily due higher sales volume inventory charges manufacturing startup costs foreign currency refer item financial statementsnote acquisitions divestitures licensing arrangements information cost products sold increased due higher eliquis profit sharing million lower foreign currency hedge settlement gains higher puerto rico excise tax marketing selling administrative marketing selling administrative expenses primarily include salary benefit costs thirdparty professional marketing fees outsourcing fees shipping handling costs advertising product promotion expenses managed regional commercialization organizations global enabling functions finance legal information technology human resources certain expenses shared alliance partners based upon contractual agreements expenses typically vary periods due new product launch promotional activities marketing selling administrative expenses decreased due lower advertising promotion salesforce expenses supporting daklinza established brands lower bms foundation grants marketing selling administrative expenses increased due higher advertising promotion salesforce expenses supporting opdivo partially offset lower spend established brands favorable foreign exchange research development research development activities include discovery research preclinical clinical development drug formulation medical support marketed products expenses include salary benefit costs thirdparty grants fees paid clinical research organizations supplies upfront contingent milestone payments licensing asset acquisitions investigational compounds iprd impairment charges proportionate allocations enterprisewide costs allocations include facilities information technology employee stock compensation costs appropriate costs certain expenses shared alliance partners based upon contractual agreements expenses typically vary periods number reasons including timing license asset acquisition charges iprd impairment charges research development expenses increased due higher license asset acquisition charges site exit charges iprd impairment charges expansion opdivo io development programs research development expenses decreased due lower license asset acquisition iprd impairment charges partially offset acceleration expansion opdivo development programs significant charges included rd expense follows year ended december dollars millions ifm cytomx halozyme flexus b b cardioxyl b psioxus ono padlock cormorant nitto denko five prime promedior c bavarian nordic c uniqure license asset acquisition charges fstar alpha lpa antagonist iprd impairments site exit costs site exit costs research development significant charges upfront payment b milestone payment c option fee license asset acquisition charges resulted strategic transactions acquire license certain investigational oncology cardiovascular immunoscience fibrotic disease compounds options acquire license disclosed acquisition licensing arrangements iprd impairment charges related discontinued development investigational compound part alliance fstar alpha lpa antagonist phase ii study site exit costs resulted expected exit rd sites us primarily due reduction estimated useful lives related assets impairment charge reduce carrying value rd facility wallingford connecticut income net income net increased primarily due patent infringement settlement outlicensing income partially offset lower divestiture gains related service fees higher restructuring debt redemption charges income net increased primarily due divestiture gains related service fees royalties lower debt redemption litigation charges components income net follows year ended december dollars millions interest expense investment income provision restructuring litigation settlements equity net income affiliates divestiture gains royalties licensing income transition service fees pension charges intangible asset impairment equity investment impairment written option adjustment loss debt redemption income net restructuring charges relate changes company 's operating model drive continued success near longterm focused investment commercial opportunities key brands markets competitive agile rd organization accelerate pipeline streamline operations realign manufacturing capabilities broaden biologics capabilities reflect current future portfolio well streamline simplify smallmolecule supply network new operating model expected enable company deliver strategic financial operational flexibility necessary invest highest priorities across company aggregate restructuring charges million incurred actions including accelerated depreciation impairment charges resulting early site exits litigation settlements include bms 's share patentinfringement settlement related merck 's pd antibody keytruda bms ono signed global patent license agreement merck merck made initial payment million bms ono bms received million merck also obligated pay ongoing royalties global sales keytruda january december january december companies also granted certain rights respective patent portfolios pertaining pd payments royalties shared bms ono percent allocation respectively adjusting parties ' legal fees divestiture gains relate additional contingent consideration diabetes business certain otc brands investigational hiv medicines businesses mount vernon indiana manufacturing facility erbitux ixempra certain otc product businesses royalties licensing income include upfront licensing fees biogen roche connection outlicensing certain investigational genetically defined disease compounds royalties merck patent infringement settlement contingent consideration erbitux diabetes business divestitures including transfer certain royalty rights pertaining amylin product sales transition service fees included fees resulting divestiture diabetes investigational hiv medicines businesses pension charges consist primarily settlement charges due magnitude lump sum payments principal us pension plan written option adjustment includes income million resulting change fair value written option liability attributed reckitt alliance loss debt redemption resulted repurchase certain longterm debt obligations early redemption euro notes tender offer certain debt securities income taxes dollars millions earnings income taxes provision income taxes effective tax rate new tax reform legislation us enacted december known tax cuts jobs act act act moves worldwide tax system quasiterritorial tax system comprises broad complex changes us tax code including limited reducing us tax rate adding deemed repatriation transition tax certain foreign earnings profits generally eliminating us federal income taxes dividends foreign subsidiaries including certain income controlled foreign companies us taxable income creating new minimum tax referred base erosion antiabuse income tax limiting certain researchbased credits eliminating domestic manufacturing deduction although many aspects act effective additional tax expense billion recognized fourth quarter upon enactment act additional expense increased effective tax rate included billion onetime deemed repatriation transition tax previously untaxed post foreign earnings profits including related tax reserves earnings effectively taxed rate extent specified foreign corporations held cash certain assets rate remaining earnings profits remaining million additional tax expense included adjustment measure net deferred tax assets new us tax rate accounting reduction deferred tax assets tax rate complete tax charge deemed repatriation tax incomplete recorded provisional amount able make reasonable estimate tax provisional amounts may change completed upon finalizing untaxed post foreign earnings profits related cash certain eligible assets specified foreign corporations provisional amounts may also change additional guidance relevant tax code released excluding transitional impacts related act tax impact attributed nondeductible rd charges divestiture transactions specified items increased effective tax rate tax benefits attributed rd charges incurred connection acquisitions ifm cormorant padlock cardioxyl flexus warrant acquire promedior lower nondeductible goodwill allocated business divestitures higher valuation allowances attributed capital loss carryforwards released impacted effective tax rate addition adoption amended income tax accounting guidance related sharebased payments early adoption intraentity transfers assets inventory reduced effective tax rate earnings mix high low tax jurisdictions domestic manufacturing deductions higher us foreign tax credits resulting puerto rico excise tax attributed remaining changes effective tax rates prior act effective income tax rate typically lower us statutory rate primarily due earnings certain manufacturing operations low tax jurisdictions switzerland ireland puerto rico indefinitely reinvested bms operates favorable tax grant puerto rico scheduled expire prior although company continues assess broad complex changes us tax code currently expects significant net impact tax reform effective tax rate refer item financial statementsnote income taxes information nongaap financial measures nongaap financial measures including nongaap earnings related eps information adjusted exclude certain costs expenses gains losses specified items evaluated individual basis items adjusted considering quantitative qualitative aspects typically one following characteristics highly variable difficult project unusual nature significant results particular period indicative future operating results similar charges gains recognized prior periods likely reoccur future periods including restructuring costs accelerated depreciation impairment property plant equipment intangible assets rd charges connection acquisition licensing third party intellectual property rights divestiture gains losses pension legal contractual settlement charges debt redemption gains losses among items deferred current income taxes attributed items also adjusted considering individual impact overall tax expense deductibility jurisdictional tax rates nongaap information intended portray results baseline performance supplement enhance management analysts investors ' overall understanding underlying financial performance facilitate comparisons among current past future periods example nongaap earnings eps information indication baseline performance items considered us reflective ongoing results addition information among primary indicators use basis evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods information intended considered isolation substitute net earnings diluted eps prepared accordance gaap specified items follows year ended december dollars millions impairment charges accelerated depreciation shutdown costs cost products sold marketing selling administrative license asset acquisition charges iprd impairments site exit costs research development provision restructuring litigation settlements divestiture gains royalties licensing income pension charges intangible asset impairment written option adjustment loss debt redemption income net increase pretax income income taxes items income taxes attributed us tax reform income taxes increase net earnings noncontrolling interest increase net earnings used diluted nongaap eps calculation reconciliations gaap nongaap follows year ended december dollars millions except per share data net earnings attributable bms used diluted eps calculation gaap specified items net earnings attributable bms used diluted eps calculation nongaap average common shares outstanding diluted diluted eps attributable bms gaap diluted eps attributable specified items diluted eps attributable bms nongaap financial position liquidity capital resources net cash position follows dollars millions cash cash equivalents marketable securities current marketable securities noncurrent total cash cash equivalents marketable securities shortterm debt obligations longterm debt net cash position cash cash equivalents marketable securities held us approximately billion december remaining billion held primarily lowtax jurisdictions subject restrictions withholding taxes certain jurisdictions subject onetime deemed repatriation transition tax billion payable eight years result us tax reform however expect flexibility accessing cash future cash may generated foreign subsidiaries believe existing cash cash equivalents marketable securities together cash generated operations issuance commercial paper us sufficient satisfy normal cash requirements least next years including dividends capital expenditures milestone payments working capital deemed repatriation transition tax maturities longterm debt management continuously evaluates companys capital structure ensure company financed efficiently may result repurchase common stock debt securities termination interest rate swap contracts prior maturity issuance debt securities company repurchased billion common stock accelerated share repurchase agreements rule b plans open market purchases stock repurchases funded billion new longterm debt cash company repaid million longterm debt maturity repurchased million longterm debt refer item financial statementsnote financial instruments fair value measurements note equity information issued commercial paper fund nearterm domestic liquidity requirements average amount commercial paper outstanding million weightedaverage rate maximum amount commercial paper outstanding billion million outstanding december dividend payments billion billion dividend decisions made quarterly basis board directors annual capital expenditures approximately billion billion million expected approximately billion million continue expand biologics manufacturing capabilities facilityrelated activities example constructing new largescale biologics manufacturing facility ireland produce multiple therapies growing biologics portfolio completed investment portfolio includes noncurrent marketable securities subject changes fair value result interest rate fluctuations market factors investment policy establishes limits amount time maturity investments institution policy also requires investments entered corporate financial institutions meet high credit quality standards refer item financial statementsnote financial instruments fair value measurements information currently three separate revolving credit facilities totaling billion syndicate lenders facilities provide customary terms conditions financial covenants day billion facility expires march two billion facilities extended october july two billion fiveyear facilities extendable annually one year anniversary date consent lenders borrowings outstanding revolving credit facility december additional regulations us could passed future including additional healthcare reform initiatives changes tax laws additional pricing laws potential importation restrictions may reduce results operations operating cash flow liquidity financial flexibility continue monitor potential impact economic conditions certain european countries related impact prescription trends pricing discounts creditworthiness customers believe economic conditions material impact liquidity cash flow financial flexibility credit ratings bms 's longterm shortterm credit ratings assigned moody 's investors service prime respectively stable rating outlook bms 's longterm shortterm credit ratings assigned standard poor 's respectively stable rating outlook bms 's longterm shortterm credit ratings assigned fitch f respectively stable rating outlook longterm ratings reflect agencies ' opinion low default risk somewhat susceptible adverse effects changes circumstances economic conditions shortterm ratings reflect agencies ' opinion good extremely strong capacity timely repayment credit rating downgrade may affect interest rate debt may incur fair market value existing debt ability access capital markets generally cash flows following discussion cash flow activities dollars millions cash flow provided byused operating activities investing activities financing activities operating activities cash flow operating activities represents cash receipts disbursements activities investing financing activities operating cash flow derived adjusting net earnings noncontrolling interest noncash operating items gains losses attributed investing financing activities changes operating assets liabilities resulting timing differences receipts payments cash transactions recognized results operations result changes cash operating activities reflect timing cash collections customers alliance partners payments suppliers alliance partners employees customer discounts rebates tax payments ordinary course business example annual employee bonuses typically paid first quarter subsequent year addition cash collections impacted longer payment terms certain biologic products us primarily certain products including opdivo yervoy empliciti days days longer payment terms used closely align insurance reimbursement timing physicians cancer centers following administration patients billion change cash flow operating activities compared primarily attributable following items addition increased sales timing cash collections payments ordinary course business lower income tax payments approximately billion outlicensing proceeds million related biogen roche transactions litigation settlement proceeds million related merck 's pd antibody keytruda bms 's share partially offset higher rd licensing payments approximately million primarily due cytomx halozyme nitto denko transactions higher contributions pension plans approximately million billion change cash flow operating activities compared primarily attributable following items addition increased sales timing cash collections payments ordinary course business winddown abilify alliance approximately million lower rd licensing payments approximately million primarily due fiveprime promedior transactions partially offset higher income tax payments approximately billion investing activities cash requirements investing activities include cash used acquisitions manufacturing facilityrelated capital expenditures purchases marketable securities maturities greater days reduced proceeds business divestitures including royalties sale maturity marketable securities billion change cash flow investing activities compared primarily attributable lower net sales marketable securities maturities greater days million essentially offset changes cash equivalents lower business divestiture proceeds approximately million primarily due certain otc brands investigational hiv medicines businesses higher asset acquisition payments approximately million primarily due acquisition ifm billion change cash flow investing activities compared primarily attributable higher net sales marketable securities approximately billion reinvested cash cash equivalents lower asset acquisition payments approximately million primarily due acquisition flexus higher business divestiture proceeds approximately million including royalties contingent consideration received subsequent divestitures certain otc brands investigational hiv medicines businesses mount vernon indiana manufacturing facility ixempra mature otc product businesses partially offset higher capital expenditures approximately million financing activities cash requirements financing activities include cash used pay dividends repurchase common stock repay longterm debt borrowings reduced proceeds exercise stock options issuance longterm debt borrowings billion change cash flow financing activities compared primarily attributable higher repurchase common stock billion primarily due accelerated share repurchase agreements partially offset higher net borrowing activity million primarily fund repurchase common stock billion change cash flow financing activities compared primarily attributable higher net borrowing activity approximately billion primarily due debt redemptions reductions cash overdrafts partially offset repurchase common stock approximately million none contractual obligations offbalance sheet arrangements payments due period contractual obligations december follows obligations expiring period dollars millions total later years shortterm borrowings longterm debt interest longterm debta operating leases purchase obligations uncertain tax positionsb deemed repatriation transition tax total c includes estimated future interest payments periodic cash settlements derivatives b includes shortterm uncertain tax benefits uncertainties regarding timing resolution c excludes pension liabilities uncertainties regarding timing resolution addition committed aggregated billion potential future research development milestone payments third parties licensing asset acquisitions development programs including earlystage milestones billion milestones achieved phase iii clinical studies latestage milestones billion milestones achieved post phase iii clinical studies payments generally due payable upon achievement certain developmental regulatory milestones specific timing predicted agreements also provide salesbased milestones aggregating billion would obligated pay alliance partners upon achievement certain sales levels addition royalties also certain manufacturing development commercialization obligations connection alliance arrangements practicable estimate amount obligations refer item financial statementsnote alliances information regarding alliances offbalance sheet arrangements material reasonably likely become material financial condition results operations sec consent order fcpa settlement previously disclosed august entered final settlement sec concluding investigation concerning certain wholesaler inventory accounting matters settlement reached consent copy attached exhibit quarterly report form q period ended september terms consent agreed subject certain defined exceptions limit sales products sold direct customers including wholesalers distributors hospitals retail outlets pharmacies government purchasers based expected demand amounts exceed approximately one month inventory hand without making timely public disclosure change practice also agreed consent certain measures implemented including establishing formal review certification process annual quarterly reports filed sec b establishing business risk disclosure group c retaining outside consultant comprehensively study help reengineer accounting financial reporting processes publicly disclosing sales incentives offered direct customers purpose inducing purchase products excess expected demand e ensuring budget process gives appropriate weight inputs come bottom top top bottom adequately documenting process established companywide policy limit sales direct customers purpose complying consent policy includes adoption various procedures monitor limit sales direct customers accordance terms consent procedures include governance process escalate appropriate management levels potential questions concerns regarding compliance policy timely resolution questions concerns addition compliance policy monitored regular basis maintain dsas us pharmaceutical wholesalers account nearly gross us revenues current terms dsas wholesaler customers provide us weekly information respect months hand productlevel inventories amount outmovement products three largest wholesalers currently account approximately gross us revenues inventory information received wholesalers together internal information used estimate months hand product level inventories wholesalers estimate months hand product inventory levels us businesss wholesaler customers three largest wholesalers extrapolating months hand calculated three largest wholesalers contrast nonus business significantly direct customers limited information direct customer product level inventory corresponding outmovement information reliability thirdparty demand information available varies widely accordingly rely variety methods estimate months hand product level inventories business units believe abovedescribed procedures provide reasonable basis ensure compliance consent addition previously disclosed october company reached civil settlement sec alleged fcpa violations company agreed pay approximately million disgorgement penalties interest part settlement company agreed twoyear selfmonitoring period reporting government concluded october recently issued accounting standards recently issued accounting standards refer item financial statementsnote accounting policiesrecently issued accounting standards critical accounting policies preparation financial statements requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses critical accounting policies significantly impact financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain uncertainty actual results may vary estimates revenue recognition accounting policy revenue recognition substantial impact reported results relies certain estimates revenue recognized persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally upon shipment except certain eu markets occur delivery products customer revenue also reduced gtn sales adjustments discussed involve significant estimates judgment considering legal interpretations applicable laws regulations historical experience payer channel mix eg medicare medicaid current contract prices applicable programs unbilled claims processing time lags inventory levels distribution channel estimates assessed period adjusted required revise information actual experience gtn adjustments following categories gtn adjustments involve significant estimates judgments information obtained external sources refer total revenues discussion analysis significant category gtn sales adjustments chargebacks cash discounts us business participates programs government entities significant us department defense us department veterans affairs parties including covered entities b drug pricing program whereby pricing products extended wholesaler list price participating entities entities purchase products wholesalers lower program price wholesalers charge us difference acquisition cost lower program price accounts receivable reduced estimated amount unprocessed chargeback claims attributable sale typically within two four week time lag us certain countries cash discounts offered incentive prompt payment generally approximating sales price accounts receivable reduced estimated amount unprocessed cash discounts typically within one month time lag medicaid medicare rebates us business participates state government medicaid programs qualifying federal state government programs requiring discounts rebates participating state local government entities discounts rebates provided programs included medicaid rebate accrual medicaid rebates also extended drugs used managed medicaid plans estimated amount unpaid unbilled rebates presented liability rebates discounts offered managed healthcare organizations us managing prescription drug programs medicare advantage prescription drug plans covering medicare part drug benefit also pay point service discount centers medicare medicaid services medicare part beneficiaries coverage gap donut hole estimated amount unpaid unbilled rebates discounts presented liability rebates returns discounts adjustments gtn sales adjustments include sales returns programs based applicable laws regulations individual nonus countries well rebates offered managed healthcare organizations us lesser extent nonus programs include several different pricing schemes cost caps volume discounts outcomebased pricing schemes pricing clawbacks based sales individual companies aggregation companies participating specific market estimated amount unpaid unbilled rebates discounts presented liability estimated returns established products determined considering historical experience factors including levels inventory distribution channel estimated shelf life product recalls product discontinuances price changes competitive products introductions generic products introductions competitive new products lower demand following loe estimated amount product returns presented liability estimated returns new products determined considering historical sales return experience similar products within product line similar therapeutic area andor similar distribution model defer recognition revenue right return expires sufficient historical experience estimate sales returns developed limited circumstances insufficient historical experience products similar therapeutic area distribution method characteristic available typically occurs new product extension existing line product historical experience products similar therapeutic category lacking estimated levels inventory distribution channel projected demand also considered estimating sales returns new products use information external sources information external sources used estimate gtn adjustments estimate inventory wholesalers based projected prescription demand based sales products historical inventory experience well analysis thirdparty information including written oral information obtained certain wholesalers respect inventory levels sellthrough customers thirdparty market research data internal information inventory information received wholesalers product recordkeeping process excludes inventory held intermediaries sell retailers hospitals also continued practice combining retail mail prescription volume retailequivalent basis use methodology internal demand forecasts also use information external sources identify prescription trends patient demand average selling prices estimates subject inherent limitations estimates rely thirdparty information certain thirdparty information form estimates reflect limitations including lags date thirdparty information generated date receive thirdparty information retirement benefits accounting pension postretirement benefit plans requires actuarial valuations based significant assumptions discount rates expected longterm rates return plan assets consultation actuaries significant assumptions others salary growth retirement turnover healthcare trends mortality rates evaluated selected based expectations actual experience remeasurement date pension expense could vary within range outcomes material effect reported earnings projected benefit obligations future cash funding actual results given year may differ estimated economic factors yield high quality corporate bonds coincides cash flows plans estimated payouts used determining discount rate citi pension discount curve used us plans present value benefit obligations december us pension plans determined using discount rate assumed discount rate used determining us pension plans projected benefit obligation december reduced additional projected benefit obligation would increase approximately million expected longterm rate return plan assets estimated considering expected returns individual asset classes input external advisors also consider longterm historical returns including actual performance compared benchmarks similar investments us plans pension expense determined using expected longterm rate return plan assets expected longterm rate return plan assets used determining us plans pension expense reduced expense would increase million detailed discussion retirement benefits refer item financial statementsnote pension postretirement postemployment liabilities business combinations divestitures goodwill intangible assets acquired business combinations licensing transactions billion representing total assets december accounting transactions business combinations divestitures significantly different asset acquisitions divestitures example acquired iprd capitalized business combinations expensed asset acquisitions fair value contingent consideration goodwill recognized business combination transactions likewise portion reporting unit constitutes business divested goodwill associated business included carrying value business determining gain loss derecognition goodwill occur asset dispositions result important determine whether business asset group assets acquired divested business defined asc business combinations integrated set inputs processes capable generating outputs ability provide return investors owners typical inputs include longlived assets including intangible assets rights use longlived assets intellectual property ability obtain access required resources typical processes include strategic operational resource management processes typically documented evident organized workforce consider factors determining whether business acquired divested well compound 's development phase commercial products involved example evaluating acquisitions ifm cormorant padlock cardioxyl flexus past three years concluded significant processes transferred us thus transactions accounted asset acquisitions result amounts allocated lead investigational compounds expensed capitalized addition contingent consideration potential development regulatory approval sales based milestones salesbased royalties included purchase price refer item financial statementsnote acquisitions divestitures discussion acquisitions similarly evaluating divestitures small molecule manufacturing operations swords ireland investigational hiv medicines business businesses comprising alliance reckitt medicines company valeant pharmaceuticals international inc erbitux ixempra concluded necessary inputs processes transferred consequently transactions accounted sales businesses resulted allocation goodwill million million million carrying value businesses determining gain sale contingent proceeds related divestitures recognized realized also concluded inputs significant processes capable generating outputs transferred outlicensing arrangements biogen roche consequently transactions accounted sales businesses longlived assets intangible assets including iprd intangible assets billion december including licenses million million allocated unapproved products developed technology rights million capitalized software million iprd million intangible assets assessed impairment whenever current facts circumstances warrant review although iprd assessed least annually intangible assets highly vulnerable impairment charges particularly newly acquired assets recently launched products iprd assets initially measured fair value therefore reduction expectations used valuations could potentially lead impairment common potential risks leading impairment include competition earlier expected loe pricing pressures adverse regulatory changes clinical study results delay failure obtain regulatory approval additional development costs inability achieve expected synergies higher operating costs changes tax laws macroeconomic changes complexity estimating fair value intangible assets connection impairment test similar initial valuation considering high risk nature research development industrys success rate bringing developmental compounds market impairment charges likely occur future periods recognized million charge fstar alpha 's fs phase development treatment breast gastric cancer million bms phase ii development treatment ipf discussion iprd impairments refer item financial statementsnote goodwill intangible assets property plant equipment property plant equipment tested impairment whenever current facts circumstances require review including whether likely asset disposed prior estimated remaining useful life additionally longlived assets periodically reviewed determine change facts circumstances would result change estimated useful life asset possibly resulting acceleration depreciation circumstances exist estimate undiscounted future cash flows generated asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value expectations future cash flows subject change based upon near longterm production volumes margins generated asset well potential alternative future use divestiture small molecule active pharmaceutical ingredient manufacturing operations swords ireland sale rd facility wallingford connecticut resulted million million impairment charges respectively reduce carrying value assets heldforsale fair value accelerated depreciation impairment related charges certain manufacturing rd facilities million million million additional charges continue occur result companys restructuring actions announced fourth quarter assets heldforsale following criteria considered concluding assets classified heldforsale managements commitment plan sell availability immediate sale present condition initiation active program identify buyer probability completed sale within one year actively marketed sale reasonable price relation current fair value likelihood significant changes plan made plan withdrawn criteria met balance sheet date net assets presented separately balance sheet heldforsale lower carrying amount fair value less costs sell longer depreciated amortized classified heldforsale example evaluating divestitures small molecule manufacturing operations swords ireland sale rd facility wallingford connecticut concluded necessary heldforsale criteria met quarterly period prior completed sale evaluating divestitures investigational hiv medicines business businesses comprising alliances reckitt lilly concluded necessary heldforsale criteria met income taxes valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecasts future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made deferred tax assets billion december net valuation allowances billion billion december net valuation allowances billion us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives discussed fully results operations section mda tax charges attributed onetime deemed repatriation tax certain foreign earnings billion recognized fourth quarter accounting income tax effect act incomplete issuance date financial statements necessary information available prepared analyzed complete accounting however able make reasonable estimate tax recorded provisional amount provisional amount may change completed upon finalizing taxable income untaxed post foreign earnings profits related cash certain eligible assets specified foreign corporations provisional amounts may also change additional interpretations relevant tax code released prior mead johnson splitoff following transactions occurred internal spinoff mead johnson shares still owned us ii conversion mead johnson class b shares class shares iii conversion mead johnson company limited liability company transactions well splitoff mead johnson exchange offer qualify taxexempt transactions internal revenue code based upon private letter ruling received internal revenue service related conversion mead johnson class b shares class shares outside legal opinions certain assumptions representations covenants mead johnson relied upon regarding future conduct business matters could affect tax treatment exchange example current tax law generally creates presumption exchange would taxable us mead johnson shareholders engage transactions result greater change stock ownership four year period beginning two years exchange offer unless established exchange offer part plan series related transactions effect change ownership internal spinoff exchange offer determined qualify tax exempt transaction transaction could subject tax exchange taxable sale us market value addition negative basis excess loss account ela existed investment stock mead johnson prior transactions received opinion outside legal counsel effect likely eliminated ela part transactions taxable income respect ela tax law area complex possible even internal spinoff exchange offer tax exempt internal revenue code irs could assert additional taxable income period respect ela could exposed additional taxes occur based upon understanding internal revenue code opinion outside legal counsel tax reserve million established reducing gain disposal mead johnson included discontinued operations agreed certain tax related indemnities mead johnson set forth tax sharing agreement including certain taxes related business prior completion ipo created part restructuring facilitate ipo mead johnson also agreed indemnify us potential tax effects resulting breach certain representations discussed well certain transactions related acquisition mead johnsons stock assets liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credits deductibility certain expenses liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known discussions income taxes refer item financial statementsnote accounting policiesincome taxes note income taxes contingencies normal course business subject contingencies legal proceedings claims arising business cover wide range matters including among others government investigations shareholder lawsuits product environmental liability contractual claims tax matters recognize accruals contingencies probable liability incurred amount loss reasonably estimated estimates subject uncertainties difficult predict actual results could vary estimates discussions contingencies refer item financial statementsnote accounting policiescontingencies note income taxes note legal proceedings contingencies product pipeline developments rd programs managed portfolio basis early discovery latestage development include balance earlystage latestage programs support future growth late stage rd programs phase iii development include investigational compounds initial indications additional indications formulations marketed products spending programs represent approximately annual rd expenses last three years opdivo investigational compound marketed product represented greater rd expenses last three years latestage development programs could potentially impact revenue earnings within next years regulatory approvals obtained products successfully commercialized following developments marketed products latestage pipeline product indication date developments bms ono announced opdivo designated treatment biliary tract cancer sakigake biliary tract cancer april designation system japan offers priority consultation review bms seattle genetics inc highlighted updated interim results phase iii study evaluating december opdivo adcetris relapsedrefractory chl interim results previously highlighted june bms announced extended followup data checkmate phase ii study evaluating opdivo patients june relapsed progressed chl autologous stem cell transplant chl bms seattle genetics inc expanded clinical collaboration evaluate combination opdivo june adcetris brentuximab vedotin pivotal phase iii study relapsedrefractory transplant advanced chl fda approval updated indication opdivo treatment adult patients chl april relapsed progressed autohsct brentuximab vedotin three lines systemic therapy includes autohsct approval japan treatment unresectable advanced recurrent gastric cancer progressed september chemotherapy received alliance partner ono gastric announced results ono phase iii study evaluating opdivo patients previously treated january advanced gastric cancer refractory intolerant standard therapy ono alliance partner conducted study announced checkmate randomized phase iii study evaluating efficacy safety opdivo gbm april patients first recurrence gbm meet primary endpoint improved overall survival bevacizumab monotherapy fda approval treatment patients hcc type liver cancer previously treated hcc september sorafenib april ec approval treatment scchn adults progressing platinumbased therapy hnc march approval treatment recurrent metastatic hnc japan received alliance partner ono announced data cohort phase iii checkmate study evaluating opdivo treatment hpv june opdivo patients advanced cervical vaginal vulvar cancers associated infection hpv fda approval treatment adult pediatric patients msih dmmr mcrc mcrc august progressed following treatment fluoropyrimidine oxaliplatin irinotecan fda approval injection intravenous use adjuvant treatment patients melanoma december involvement lymph nodes metastatic disease undergone complete resection announced ema validated type ii variation application seeks expand current indications october include treatment patients melanoma high risk disease recurrence following complete surgical resection announced treatment opdivo resulted significant improvement recurrencefree survival compared september melanoma yervoy patients stage iiibc stage iv melanoma following complete surgical resection announced phase iii study evaluating opdivo versus yervoy patients stage iiibc stage iv july melanoma high risk recurrence following complete surgical resection met primary endpoint recurrencefree survival planned interim analysis announced proofofconcept data phase iiia study opdivo combination bms june investigational antilag therapy patients advanced melanoma previously treated antipdpd l therapy ec approval treatment patients previously treated locally advanced unresectable muc type june bladder cancer adults failure platinumcontaining therapy muc fda approval treatment patients previously treated locally advanced metastatic urothelial february carcinoma type bladder cancer announced fda lifted partial clinical holds placed checkmate ca two clinical studies december investigating opdivo based combinations patients relapsed refractory multiple myeloma announced fda placed partial clinical holds checkmate checkmate ca three multiple myeloma clinical studies investigating opdivo based combinations patients relapsed refractory multiple september myeloma partial clinical hold related risks identified studies studying another antipd agent pembrolizumab patients multiple myeloma announced phase iii study checkmate multinational randomized study evaluating opdivo versus docetaxel previously treated advanced metastatic nsclc stopped early met primary november endpoint demonstrating superior overall survival checkmate multinational phase iii study predominately chinese patients bms submitted bla opdivo china food drug administration cfda proposed indication previously treated nsclc accepted cfda nsclc announced threeyear overall survival data checkmate checkmate two pivotal phase iii september randomized studies evaluating opdivo vs docetaxel patients previously treated metastatic nsclc announced fiveyear overall survival data study ca phase study evaluating opdivo april patients previously treated advanced nsclc announced threeyear overall survival update checkmate phase iii study evaluating opdivo vs opdivo rcc november everolimus previously treated advanced rcc bms clovis oncology inc announced clinical collaboration evaluate combination opdivo rubraca rucaparib pivotal phase iii studies advanced ovarian cancer triplenegative breast cancer well phase ii study metastatic castrationresistant prostate cancer july announced fda accepted company 's sblas update opdivo dosing include mg infused various minutes every four weeks currently approved monotherapy indications fda action date march bms incyte announced companies advance clinical development program evaluating april combination opdivo epacadostat phase iii registrational study firstline nsclc across spectrum pdl expression firstline hnc announced new data checkmate phase ii study evaluating opdivo monotherapy combination crc january yervoy previously treated patients dmmr msih metastatic crc interim data previously announced june announced efficacy data checkmate phase ii study evaluating opdivoyervoy potential june treatment patients melanoma metastatic brain melanoma announced overall survival data checkmate phase iii study evaluating opdivo alone april combination yervoy patients previously untreated advanced melanoma announced results ifct maps study evaluating opdivo opdivo combined yervoy mpm june previously treated unresectable mpm patients announced pivotal phase iii checkmate study demonstrated superior progressionfree survival combination opdivoyervoy versus chemotherapy firstline nsclc patients high tumor nsclc february mutation burden regardless pdl expression study continue planned assess opdivoyervoy combination coprimary endpoint overall survival patients express pdl announced fda accepted company 's sbla 's priority review opdivoyervoy treat intermediate poorrisk patients advanced rcc fda action date april november announced december results new exploratory analysis pdl expression subgroups phase iii checkmate study evaluating opdivoyervoy vs standard care sunitinib intermediate poorrisk patients previously untreated advanced metastatic rcc opdivoyervoy announced ema validated type ii variation application seeks expand current indications november opdivoyervoy include treatment intermediate poorrisk patients advanced rcc announced checkmate phase iii study evaluating opdivoyervoy versus sunitinib patients previously untreated advanced metastatic rcc met coprimary endpoint demonstrating superior overall rcc september survival intermediate poorrisk patients combination also met secondary endpoint improved overall survival randomized patients based planned interim analysis independent data monitoring committee recommended study stopped early announced topline results checkmate combination opdivoyervoy met coprimary august endpoint objective response rate favored coprimary endpoint progressionfree survival however reach statistical significance bms exelixis inc announced initiation phase iii checkmate er study evaluate opdivo combination cabometyx cabozantinib exelixis 's small molecule inhibitor receptor tyrosine kinases july opdivo yervoy combination cabometyx versus sunitinib patients previously untreated advanced metastatic rcc announced data evaluating opdivo opdivoyervoy previously treated sclc patients whose tumors sclc october evaluable tumor mutation burden phase iii checkmate study bms exelixis announced clinical development collaboration evaluate cabometyx opdivo either various february alone combination yervoy agreement expected include phase iii study firstline rcc additional studies planned bladder cancer hcc potentially tumor types announced results realworld data analysis us humana database treatment eliquis associated significantly lower risk strokesystemic embolism lower rates major bleeding compared warfarin patients aged years older nvaf announced data emanate phase iv study exploring safety efficacy eliquis patients august nvaf undergoing cardioversion announced results realworld data analysis pooled four large us insurance claims databases eliquis nvaf treatment eliquis associated lower risk strokesystemic embolism lower rates major bleeding compared warfarin overall population selected highrisk patient sub populations announced findings realworld data analysis us medicare database comparing risk stroke march systemic embolism rate major bleeding among patients nonvalvular atrial fibrillation treated direct oral anticoagulants versus warfarin ec approval treatment active psa adults response previous diseasemodifying antirheumatic drug therapy including methotrexate inadequate additional systemic therapy psa july psoriatic skin lesions required orencia fda approval active psa adults chronic inflammatory disease affect skin musculoskeletal system fda approval new subcutaneous administration option use patients two years age older jia march moderately severely active polyarticular jia announced data phase ii ca study pediatric patients newly diagnosed philadelphia december chromosomepositive treated sprycel added chemotherapy regimen fda expanded indication sprycel tablets include treatment children philadelphia november chromosomepositive cml chronic phase sprycel announced data phase ii ca study evaluating sprycel imatinibresistant intolerant june cml newly diagnosed pediatric patients chronic phase cml announced ema validated grouped type ii variationextension application treat children may adolescents aged year years chronic phase philadelphia chromosome positive cml include powder oral suspension ec approval expanded indication treatment unresectable metastatic melanoma pediatric january patients years age older announced fda added fiveyear overall survival data phase iii ca study october prescribing information yervoy adjuvant treatment fully resected cutaneous melanoma pathologic involvement regional lymph nodes mm yervoy melanoma fda approval expanded indication treatment unresectable metastatic melanoma pediatric july patients announced relapsefree survival results phase iii study evaluating yervoy mgkg yervoy mgkg june patients stage iii resectable stage iv melanoma high risk recurrence following complete surgical resection announced fouryear followup data phase iii study evaluating empliciti plus empliciti multiple myeloma june lenalidomidedexamethasone vs lenalidomidedexamethasone alone patients relapsedrefractory multiple myeloma china fda approval daklinza sunvepra regimen treatmentnaive experienced patients infected hepatitis c hcv april genotype b chronic hcv addition daklinza approved china combination use franchise agents including sofosbuvir adult patients hcv genotypes infection bavarian nordic announced independent data monitoring committee determined continuation prostvac prostate cancer september phase iii prospect study prostvac patients metastatic castrationresistant prostate cancer futile special note regarding forwardlooking statements annual report including documents incorporated reference written oral statements make time time contain certain forwardlooking statements within meaning section securities act section e securities exchange act identify forwardlooking statements fact use words expect anticipate estimate target may project guidance intend plan believe words terms similar meaning expression connection discussion future operating financial performance one also identify forwardlooking statements fact relate strictly historical current facts forwardlooking statements based current expectations involve inherent risks uncertainties including factors could delay divert change could cause actual outcomes differ materially current expectations statements likely relate among things goals plans projections regarding financial position results operations cash flows market position product development product approvals sales efforts expenses performance results current anticipated products outcome contingencies legal proceedings financial results based current expectations involve inherent risks uncertainties including internal external factors could delay divert change next several years included important factors cautionary statements included annual report particularly item risk factors believe could cause actual results differ materially forwardlooking statement although believe prudent plans assumptions assurance given goal plan set forth forwardlooking statements achieved readers cautioned place undue reliance statements speak date made undertake obligation release publicly revisions forwardlooking statements result new information future events otherwise item quantitative qualitative disclosures market risk exposed market risk resulting changes currency exchange rates interest rates certain derivative financial instruments used available costeffective basis hedge underlying economic exposure financial instruments including derivatives subject counterparty credit risk considered part overall fair value measurement derivative financial instruments used trading purposes foreign exchange risk significant amounts revenues earnings cash flow exposed changes foreign currency rates primary net foreign currency translation exposures euro japanese yen foreign currency forward contracts used manage risk primarily arising certain intercompany purchase transactions also exposed foreign exchange transaction risk arising nonfunctional currency denominated assets liabilities earnings denominated nonus dollar currencies foreign currency forward contracts used offset exposures designated hedges estimate appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts million december reducing earnings remaining life contracts also exposed translation risk nonus dollardenominated net assets nonus dollar borrowings used hedge foreign currency exposures net investment certain foreign affiliates designated hedges net investments effective portion foreign exchange gains losses hedges included foreign currency translation component accumulated comprehensive incomeloss net investment decreases equivalent value nonus debt borrowings change remeasurement basis debt would subject recognition income changes occur additional information refer item financial statementsnote financial instruments fair value measurements interest rate risk use fixedtofloating interest rate swap contracts designated fair value hedges provide appropriate balance fixed floating rate debt estimate increase basis points shortterm longterm interest rates would decrease fair value interest rate swap contracts million thereby reducing earnings remaining life contracts estimate increase basis points longterm interest rates would decrease fair value longterm debt million marketable securities subject changes fair value result interest rate fluctuations market factors estimate increase basis points interest rates would decrease fair value debt investments approximately million credit risk monitor investments counterparties objective minimizing concentrations credit risk investment policy invest institutions meet high credit quality standards establishes limits amount time maturity investments individual counterparty policy also requires investments entered corporate financial institutions meet high credit quality standards use derivative instruments exposes us credit risk counterparty fails perform fair value derivative instrument contract positive counterparty fails perform collateral required party whether derivatives asset liability position policy diversifying derivatives counterparties mitigate overall risk counterparty defaults additional information refer item financial statementsnote financial instruments fair value measurements item financial statements supplementary data bristolmyers squibb company consolidated statements earnings dollars millions except per share data year ended december earnings net product sales alliance revenues total revenues cost products sold marketing selling administrative research development income net total expenses earnings income taxes provision income taxes net earnings noncontrolling interest net earnings attributable bms earnings per common share basic diluted cash dividends declared per common share consolidated statements comprehensive income dollars millions year ended december comprehensive income net earnings comprehensive incomeloss net taxes reclassifications earnings derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation total comprehensive incomeloss comprehensive income comprehensive incomeloss attributable noncontrolling interest comprehensive income attributable bms accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated balance sheets dollars millions except share per share data december assets current assets cash cash equivalents marketable securities receivables inventories prepaid expenses total current assets property plant equipment goodwill intangible assets deferred income taxes marketable securities assets total assets liabilities current liabilities shortterm debt obligations accounts payable accrued liabilities deferred income income taxes payable total current liabilities deferred income income taxes payable pension liabilities longterm debt total liabilities commitments contingencies equity bristolmyers squibb company shareholders equity preferred stock convertible series par value per share authorized million shares issued outstanding liquidation value per share common stock par value per share authorized billion shares billion issued capital excess par value stock accumulated comprehensive loss retained earnings less cost treasury stock million common shares million total bristolmyers squibb company shareholders ' equity noncontrolling interest total equity total liabilities equity accompanying notes integral part consolidated financial statements bristolmyers squibb company consolidated statements cash flows dollars millions year ended december cash flows operating activities net earnings adjustments reconcile net earnings net cash provided operating activities depreciation amortization net deferred income taxes stockbased compensation impairment charges pension settlements amortization divestiture gains royalties asset acquisition charges adjustments changes operating assets liabilities receivables inventories accounts payable deferred income income taxes payable net cash provided operating activities cash flows investing activities sale maturities marketable securities purchase marketable securities capital expenditures divestiture proceeds acquisition payments net cash provided byused investing activities cash flows financing activities shortterm debt obligations net issuance longterm debt repayment longterm debt repurchase common stock dividends net cash used financing activities effect exchange rates cash cash equivalents increasedecrease cash cash equivalents cash cash equivalents beginning year cash cash equivalents end year accompanying notes integral part consolidated financial statements note accounting policies recently issued accounting standards basis consolidation consolidated financial statements prepared conformity us gaap including accounts bristolmyers squibb company controlled majorityowned subsidiaries certain variable interest entities intercompany balances transactions eliminated material subsequent events evaluated disclosed report issuance date refer summary abbreviated terms end terms used throughout document alliance license arrangements assessed determine whether terms provide economic control entity requiring consolidation entity entities controlled means majority voting interest referred variable interest entities consolidated bms power direct activities variable interest entity significantly impacts economic performance obligation absorb losses right receive benefits could potentially significant entity use estimates judgments preparation financial statements requires use management estimates judgments assumptions significant assumptions estimates determining fair value potential impairment intangible assets sales rebate return accruals legal contingencies income taxes determining acquisition divestiture business asset pension postretirement benefits actual results may differ estimated results reclassifications certain prior period amounts reclassified conform current period presentation consolidated statement cash flows previously presented interest rate swap contract terminations issuance common stock separate line items within cash flows financing activities presented components financing activities reclassifications provide concise financial statements presentations additional information disclosed notes material revenue recognition revenue recognized persuasive evidence arrangement exists sales price fixed determinable collectability reasonably assured title substantially risks rewards ownership transferred generally time shipment including supply commercial products alliance partners principal end customer sale however certain revenue nonus businesses recognized date receipt customer alliance revenue related abilify atripla recognized products sold end customer alliance partner royalties recognized thirdparty sales reliably measurable collectability reasonably assured refer note alliances detail regarding alliances revenue reduced time recognition expected sales returns discounts rebates sales allowances based historical experience updated changes facts circumstances including impact applicable healthcare legislation revenue deferred historical experience products similar therapeutic category similar operational characteristics right return longer exists sufficient historical experience estimate sales returns developed income taxes provision income taxes includes income taxes paid payable current year plus change deferred taxes year deferred taxes result differences financial tax basis assets liabilities adjusted changes tax rates tax laws changes enacted valuation allowances recognized reduce deferred tax assets likely tax benefit realized assessment whether valuation allowance required often requires significant judgment including longrange forecast future taxable income evaluation tax planning initiatives adjustments deferred tax valuation allowances made earnings period assessments made tax benefits recognized uncertain tax position likely tax position sustained examination taxing authorities based technical merits position tax benefit recognized financial statements particular tax position based largest benefit likely realized upon settlement cash cash equivalents cash cash equivalents include bank deposits time deposits commercial paper money market funds cash equivalents consist highly liquid investments original maturities three months less time purchase recognized cost approximates fair value marketable securities investments companies marketable securities classified availableforsale date purchase reported fair value fair value determined based observable market quotes valuation models using assessments counterparty credit worthiness credit default risk underlying security overall capital market liquidity investments less owned companies accounted using equity method accounting ability exercise significant influence maintained share net income losses equity investments included income net equity investments reviewed impairment assessing decline market value investment carrying value temporary considers intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value less cost investee 's financial condition inventory valuation inventories stated lower average cost market property plant equipment depreciation expenditures additions renewals improvements capitalized cost depreciation computed straightline method based estimated useful lives related assets ranging years buildings years machinery equipment fixtures impairment longlived assets current facts circumstances periodically evaluated determine carrying value depreciable assets held used may recoverable circumstances exist estimate undiscounted future cash flows generated longlived asset appropriate grouping assets compared carrying value determine whether impairment exists lowest level identifiable cash flows asset determined impaired loss measured based difference assets fair value carrying value estimate assets fair value based quoted market prices active markets available quoted market prices available estimate fair value based various valuation techniques using unobservable fair value inputs discounted value estimated future cash flows capitalized software eligible costs obtain internal use software capitalized amortized estimated useful life software acquisitions businesses acquired consolidated upon obtaining control fair value assets acquired liabilities assumed recognized date acquisition excess purchase price estimated fair values net assets acquired recognized goodwill business acquisition costs expensed incurred contingent consideration potential development regulatory approval salesbased milestones salesbased royalties included purchase price business combinations excluded asset acquisitions amounts allocated lead investigational compounds asset acquisitions expensed date acquisition goodwill acquired inprocess research development intangible assets fair value acquired intangible assets typically determined using income method utilizing level fair value inputs market participant valuations assume global view considering potential jurisdictions indications based discounted aftertax cash flow projections risk adjusted estimated probability technical regulatory success iprd finitelived intangible assets including licenses developed technology rights iprd projects reach commercialization amortized straightline basis estimated useful life estimated useful lives determined considering period assets expected contribute future cash flows goodwill tested least annually impairment assessing qualitative factors performing quantitative analysis determining whether likely fair value net assets carrying amounts examples qualitative factors assessed include share price financial performance compared budgets longterm financial plans macroeconomic industry market conditions well substantial excess fair value carrying value net assets annual impairment test performed prior year relevant factor assessed individually aggregate iprd tested impairment annual basis frequently events occur circumstances change would indicate potential reduction fair values assets carrying value impairment charges recognized extent carrying value iprd determined exceed fair value finitelived intangible assets tested impairment facts circumstances suggest carrying value asset may recoverable carrying value exceeds projected undiscounted pretax cash flows intangible asset impairment loss equal excess carrying value estimated fair value discounted aftertax cash flows recognized restructuring restructuring charges recognized result actions streamline operations reduce number facilities estimating impact restructuring plans including future termination benefits exit costs requires judgment actual results could vary estimates contingencies loss contingencies legal proceedings claims may occur government investigations shareholder lawsuits product environmental liability contractual claims tax matters accruals recognized probable liability incurred amount loss reasonably estimated gain contingencies including contingent proceeds related divestitures recognized realized legal fees expensed incurred advertising product promotion costs advertising product promotion costs included marketing selling administrative expenses million million million advertising product promotion costs expensed incurred foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using current exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized oci research development research development costs expensed incurred clinical study costs accrued service periods specified contracts adjusted necessary based upon ongoing review level effort costs actually incurred research development costs presented net reimbursements alliance partners upfront contingent milestone payments asset acquisitions investigational compounds also included research development expenses alternative future uses cash flow payments licensing asset acquisitions investigational compounds included operating activities well outlicensing proceeds payments acquisition ownership interest legal entity including acquisitions meet accounting definition business included investing activities well divestiture proceeds royalties consideration received subsequent related sale asset business adjustments reflected operating activities include divestiture gains losses related royalties research development asset acquisition charges gains losses debt redemption changes fair value written option liabilities recently adopted accounting standards sharebased payment transactions amended guidance sharebased payment transactions adopted first quarter net excess tax benefits million recognized prospectively reduction tax expense rather capital excess par value stock net excess tax benefits also presented operating cash flow rather financing cash flow cash payments tax authorities connection shares withheld statutory tax withholding requirements presented financing cash flow rather operating cash flow changes cash flow presentation applied retrospectively increased operating cash flows decreased financing cash flows million million million respectively income tax accounting intraentity transfers assets inventory amended guidance income tax accounting intraentity transfers assets inventory early adopted first quarter modified retrospective approach amended guidance requires tax consequences transfers recognized period transfer takes place net reductions prepaid deferred tax assets pertaining pre internal transfers intellectual property million adjusted retained earnings cumulative effect accounting change reduce annual tax expense million beginning addition tax consequences additional internal transfers intellectual property may occur future included income tax expense upon transfer amortized subsequent periods recently issued accounting standards revenue contracts customers amended guidance revenue recognition adopted first quarter using modified retrospective method cumulative effect change recognized retained earnings new guidance referred asc requires entity recognize amount revenue expects entitled transfer promised goods services customers replaces existing revenue recognition standards us gaap five step model utilized achieve core principle identify customer contract identify contracts performance obligations determine transaction price allocate transaction price performance obligations recognize revenue performance obligation satisfied companys assessment new standards impact substantially complete timing recognizing revenue expected change typical net product sales customers existing alliance arrangements well royalties salebased milestones outlicensing arrangements addition timing recognizing royalties salesbased milestones forms contingent consideration resulting divestiture businesses expected change however transaction prices longer required fixed determinable certain variable consideration might recognized prior occurrence resolution contingent event extent probable significant reversal amount estimated cumulative revenue occur certain estimated future royalties termination fees licensing rights previously reacquired alliance partners expected recognized contract assets upon adoption new standard refer sanofi lilly arrangements note alliances result new guidance cumulative effect adjustment revenue income expected lower approximately million million respectively compared would reported previous standard significant changes business processes systems controls expected required gains losses derecognition nonfinancial assets amended guidance gains losses derecognition nonfinancial assets adopted first quarter using modified retrospective method amendments clarify scope asset derecognition guidance adds guidance partial sales nonfinancial assets clarifies recognizing gains losses transfer nonfinancial assets contracts noncustomers amended guidance clarifies certain transactions sale licensing product rights constitute business require accounting similar asc including potential recognition variable consideration amended guidance may result earlier recognition variable consideration depending facts circumstances transaction presentation net periodic pension postretirement benefits amended guidance requiring net periodic benefit components defined benefit pension postretirement plans service costs recorded outside income operations income adopted first quarter retrospective basis company expects annual cost products sold marketing selling administrative research development expenses increase aggregate corresponding offset income service cost component also included income amounts material adjusted amounts upon adoption new guidance follows year ended december dollars millions reported adjusted reported adjusted cost products sold marketing selling administrative research development income net definition business amended guidance revises definition business adopted prospectively first quarter amendments provide initial screen substantially fair value gross assets acquired disposed concentrated single identifiable asset group similar identifiable assets integrated set assets activities would represent business screen met set must include input substantive process together significantly contribute ability create outputs set represent business amendment also narrows definition term output requires transfer organized work force outputs exist amended guidance may result transactions accounted assets future impact results operations dependent individual facts circumstances transaction recognition measurement financial assets liabilities amended guidance recognition measurement presentation disclosures financial instruments adopted prospectively first quarter new guidance requires fair value adjustments equity securities readily determinable fair values currently classified availableforsale reported earnings new guidance also requires qualitative impairment assessment equity investments without readily determinable fair value based upon observable price changes charge earnings impairment exists amended guidance expected materially impact companys results operations based upon current equity investment portfolio accounting hedging activities amended guidance derivatives hedging adopted first quarter modified retrospective approach amended guidance revises expands items eligible hedge accounting simplifies hedge effectiveness testing changes timing recognition presentation certain hedged items certain disclosure requirements also modified hedging activities prospective basis amended guidance expected materially impact companys results operations leases february fasb issued amended guidance lease accounting amended guidance requires recognition rightofuse asset lease liability initially measured present value future lease payments leases term longer months guidance effective january early adoption permitted modified retrospective approach intend elect available practical expedients adoption assessment amended standard remains ongoing including continued implementation leasing software system procured rd party vendor evaluation potential changes enhancements internal controls substantially completed lease information data gathering lease data extraction processes believe overall implementation efforts remain schedule however system readiness remains critical factor ensuring successful adoption january undiscounted value lease obligations approximately million december consisting primarily facility leases accounted operating leases initial rightofuse asset lease liability amounts balance sheets upon adoption subject several factors including lease portfolio date adoption selection appropriate discount rate determining fixed lease components lease renewal periods reasonably certain occur amended guidance expected materially impact companys results operations recognition right use asset lease liability goodwill impairment testing january fasb issued amended guidance simplifies recognition measurement goodwill impairment loss eliminating step quantitative impairment test result impairment charges required amount reporting units carrying amount exceeds fair value amount allocated goodwill guidance effective prospective basis january early adoption permitted interim annual goodwill impairment tests performed january amended guidance expected materially impact companys results operations financial instruments measurement credit losses june fasb issued amended guidance measurement credit losses financial instruments entities required use forwardlooking estimated loss model availableforsale debt security credit losses recognized allowances rather reduction amortized cost guidance effective january early adoption permitted modified retrospective approach amended guidance expected materially impact companys results operations note business segment information bms operates single segment engaged discovery development licensing manufacturing marketing distribution sale innovative medicines help patients prevail serious diseases global research development organization supply chain organization responsible discovery development manufacturing supply products regional commercial organizations market distribute sell products business also supported global corporate staff functions segment information consistent financial information regularly reviewed chief executive officer purposes evaluating performance allocating resources setting incentive compensation targets planning forecasting future periods products sold principally wholesalers lesser extent directly distributors retailers hospitals clinics government agencies pharmacies gross revenues three largest pharmaceutical wholesalers us percentage global gross revenues follows mckesson corporation amerisourcebergen corporation cardinal health inc selected geographic area information follows revenues property plant equipment dollars millions united states europe rest worlda otherb total includes japan represented total revenues respectively b revenues include royalties alliancerelated revenues products sold regional commercial organizations product revenues composition total revenues follows year ended december dollars millions prioritized brands opdivo eliquis orencia sprycel yervoy empliciti established brands baraclude sustiva franchise reyataz franchise hepatitis c franchise brands total revenues net product sales alliance revenues revenues total revenues note alliances bms enters collaboration arrangements third parties development commercialization certain products although arrangements unique nature parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities bms may either inlicense intellectual property owned party outlicense intellectual property party arrangements also typically include research development manufacturing andor commercial activities cover single investigational compound commercial product multiple compounds andor products various life cycle stages rights obligations parties global limited geographic regions refer collaborations alliances partners alliance partners products sold alliance arrangements certain markets include opdivo eliquis orencia sprycel yervoy empliciti sustiva atripla certain brands payments alliance partners accounted presented results operations considering specific nature payment underlying activities payments relate multiple alliance activities including transfer rights separated individual units accounting standalone value activities occur life arrangements situations arrangement consideration allocated activities rights relative selling price basis multiple alliance activities rights standalone value combined single unit accounting common activities bms alliance partners presented results operations follows bms principal end customer sale product sales included net product sales bms 's alliance partner principal end customer sale bms 's contractual share thirdparty sales andor royalty income included alliance revenue sale commercial products considered part bms 's ongoing major central operations refer revenue recognition included note accounting policies information regarding recognition criteria amounts payable bms alliance partners principal end customer sale supply commercial products included alliance revenue sale commercial products considered part bms 's ongoing major central operations profit sharing royalties salesbased fees payable bms alliance partners included cost products sold incurred cost reimbursements parties recognized incurred included cost products sold marketing selling administrative expenses research development expenses based underlying nature related activities subject reimbursement upfront contingent development approval milestones payable bms alliance partners investigational compounds commercial products deferred amortized expected period bms 's copromotion obligation market exclusivity period periods related compounds products expected contribute future cash flows amortization presented consistent nature payment arrangement example amounts received investigational compounds presented income net activities performed time related sale commercial products part bmss ongoing major central operations amounts received commercial products presented alliance revenue sale commercial products considered part bmss ongoing major central operations except astrazeneca alliance pertaining amylin products see discussion specific astrazeneca alliance disclosure herein upfront contingent approval milestones payable bms alliance partners commercial products capitalized amortized shorter contractual term periods related products expected contribute future cash flows amortization included cost products sold upfront contingent milestones payable bms alliance partners prior regulatory approval expensed incurred included research development expenses royalties contingent consideration payable bms alliance partners related divestiture businesses included income earned equity net income affiliates included income net payments bms alliance partners presented cash flows operating activities except otherwise described selected financial information pertaining alliances follows including net product sales bms principal thirdparty customer sale products subject alliance expenses summarized include amounts attributed activities products alliance payments alliance partners related amortization payments deferred capitalized year ended december dollars millions revenues alliances net product sales alliance revenues total revenues payments tofrom alliance partners cost products sold marketing selling administrative research development income net noncontrolling interest pretax selected alliance balance sheet information december dollars millions receivables alliance partners accounts payable alliance partners deferred income alliancesa includes unamortized upfront milestone licensing proceeds revenue deferrals attributed atripla undelivered elements diabetes business divestiture proceeds amortization deferred income primarily related alliances million million million upfront payments new licensing alliance agreements including options license acquire related assets charged research development expenses million million million specific information pertaining significant alliances discussed including nature purpose significant rights obligations parties specific accounting policy elections income statement classification amounts attributable payments parties pfizer bms pfizer jointly develop commercialize eliquis anticoagulant discovered bms pfizer funds development costs depending study profits losses shared equally global basis except certain countries pfizer commercializes eliquis pays bms sales based fee coexclusive license rights granted pfizer exchange upfront payment potential milestone payments parties assumed certain obligations actively participate joint executive committee various operating committees joint responsibilities research development distribution sales marketing activities alliance using resources infrastructures bms manufactures product alliance principal end customer product sales us significant countries europe well canada australia china japan south korea bms transferred full commercialization rights pfizer certain smaller countries order simplify operations transferred countries bms supplies product pfizer cost plus percentage net sales price endcustomers company determined rights transferred pfizer standalone value rights sold separately bms party could pfizer receive benefit delivered rights without fulfillment ongoing obligations bms alliance agreement including exclusive supply arrangement global alliance treated single unit accounting upfront proceeds subsequent contingent milestone proceeds amortized expected period bms 's copromotion obligation market exclusivity period bms received million nonrefundable upfront milestone licensing payments related eliquis december amortization eliquis deferred income included income eliquis commercial product commencement alliance summarized financial information related alliance follows year ended december dollars millions revenues pfizer alliance net product sales alliance revenues total revenues payments tofrom pfizer cost products sold profit sharing income net amortization deferred income selected alliance balance sheet information december dollars millions deferred income gilead bms gilead formed joint venture us canada another joint venture europe develop commercialize combination product named atripla combines bms 's sustiva gilead 's truvada two joint ventures consolidated gilead december gilead terminated bms 's participation us canada joint venture following launch generic version sustiva thirdparty us result deferred income alliance receivables attributed sustiva product held joint venture december reduced million reflect posttermination selling price addition bms entitled fee equal atripla us net sales multiplied ratio difference average net selling prices atripla truvada atripla average net selling price fee reduced atripla us net sales multiplied ratio described bms continue supply sustiva cost plus markup gilead threeyear period unless either party elects terminate supply arrangement prior termination bms 's participation us joint venture parties actively participated joint executive committee various operating committees direct oversight activities joint venture joint venture purchased sustiva truvada api bulk form parties completed finishing atripla joint venture distributed atripla principal end customer product sales bms recorded bulk efavirenz component atripla alliance revenue based relative ratio average respective net selling prices truvada sustiva alliance revenue related alliance receivable recognized atripla sold thirdparty customers joint venture europe accounted bms continues operate similar manner described except gilead distributes atripla principal end customer product sales parties longer coordinate joint promotional activities european joint venture continue either party terminates arrangement last patent expires allows market exclusivity atripla summarized financial information related alliance follows year ended december dollars millions revenues gilead alliances alliance revenues equity net loss affiliates selected alliance balance sheet information december dollars millions deferred income otsuka bms otsuka copromote sprycel us japan eu oncology territory parties actively participate various governance committees however bms control decision making bms responsible development manufacture product also principal end customer product sales ixempra ixabepilone included alliance prior bms 's divestiture business fee paid otsuka based following percentages combined annual net sales sprycel ixempra oncology territory including post divestiture ixempra sales net sales million million million million million million billion excess billion bms also worldwide commercialization agreement otsuka codevelop copromote abilify excluding certain asian countries us portion agreement expired april eu portion expired june countries exclusive right sell abilify expiration occurred countrybycountry basis last expiration canada january parties actively participated joint executive governance operating committees otsuka responsible providing sales force efforts however bms responsible certain operating expenses various annual limits bms purchased api otsuka completed manufacturing product subsequent sale thirdparty customers us certain countries bms provided services including distribution customer management pharmacovigilance bms principal end customer product sales exclusive distributor exclusive right sell abilify otsuka principal end customer product sales us eu alliance revenue recorded bms 's share net sales thirdparty customers us eu abilify shipped risks rewards ownership transferred thirdparty customers summarized financial information related alliance follows year ended december dollars millions revenues otsuka alliances net product sales alliance revenues total revenues payments tofrom otsuka cost products sold oncology fee royalties cost product supply lilly bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux us canada japan parties actively participated joint executive committee various operating committees shared responsibilities research development using resources infrastructures lilly manufactured bulk requirements erbitux facilities filling finishing performed third party bms oversight responsibility bms exclusive distribution rights north america responsible promotional efforts north america although lilly right copromote us expense bms principal end customer product sales north america paid lilly distribution fee erbitux net sales north america plus share certain royalties paid lilly bmss rights obligations respect commercialization erbitux north america would expired september october bms transferred rights erbitux north america lilly exchange salesbased royalties described transferred rights include limited full commercialization manufacturing responsibilities transaction accounted business divestiture resulted noncash charge million intangible assets directly related business allocation goodwill bms receive royalties september included income earned royalty rates applicable north america erbitux net sales million million million million plus net sales excess amounts respective years royalties earned million million million bms shared rights erbitux japan agreement lilly merck kgaa received pretax profit merck kgaas net sales erbitux japan shared equally lilly bms transferred cocommercialization rights japan merck kgaa exchange sales based royalties included income earned royalties earned million million million result adoption asc first quarter estimated future royalties resulting transfer rights merck kgaa recorded cumulative effect adjustment retained earnings subsequent changes estimates recorded income net summarized financial information related alliance follows year ended december dollars millions revenues lilly alliance net product sales alliance revenues total revenues cost products sold income net royalties divestiture loss astrazeneca prior diabetes business divestiture discussed bms alliance astrazeneca consisting three worldwide codevelopment commercialization agreements covering onglyza related combination products sold various names farxiga related combination products beginning august bms 's acquisition amylin amylin 's portfolio products including bydureon byetta symlin myalept well certain assets owned amylin including manufacturing facility located west chester ohio february bms astrazeneca terminated alliance agreements bms sold astrazeneca substantially diabetes business comprising alliance divestiture included shares amylin resulting transfer ohio manufacturing facility intellectual property related onglyza farxiga including bms 's interest outlicensing agreement onglyza japan purchase bmss manufacturing facility located mount vernon indiana substantially employees dedicated diabetes business transferred astrazeneca bms astrazeneca entered several agreements connection sale including supply agreement development agreement transitional services agreement agreements bms obligated supply certain products perform ongoing development activities certain clinical study programs provide transitional services accounting financial services customer service distribution regulatory development information technology certain administrative services various periods order facilitate orderly transfer business operations consideration transaction includes billion payment closing contingent regulatory salesbased milestone payments billion including million related approval milestones million related salesbased milestones payable royalty payments based net sales payments million certain assets transferred astrazeneca astrazeneca also pay bms required product supply price approximating product cost well negotiated transitional service fees royalty rates net sales follows onglyza farxiga worldwide net sales million onglyza farxiga worldwide net sales million amylin products us net sales stock asset purchase agreement contained multiple elements delivered subsequent closing transaction including china diabetes business transferred mount vernon indiana manufacturing facility transferred activities development supply agreements elements determined standalone value result portion consideration received closing allocated undelivered elements using relative selling price method determining best estimated selling price element remaining amount consideration included calculation gain sale diabetes business contingent milestone royalty payments similarly allocated among underlying elements amounts determined payable bms amounts allocated sale business immediately recognized results operations amounts allocated elements recognized results operations extent element delivered consideration million received transfer mount vernon indiana manufacturing facility related inventories resulting gain million amounts allocated delivered elements contingent consideration million received astrazeneca upon achievement regulatory approval milestone resulting additional gain consideration allocated development supply agreements amortized applicable service periods amortization deferred income attributed development agreement ended december included income sale services considered part bmss ongoing major central operations amortization deferred income attributed supply agreement ended december recorded alliance revenues revenues attributed supply agreement included alliance revenues consideration transaction presented cash flow purposes based allocation process described either investing activity attributed sale business related assets operating activity attributed transitional services supply arrangement development agreement september bms transferred percentage future royalty rights amylin net product sales us cppib transferred rights represent approximately potential future royalties bms entitled exchange transfer bms receive additional tieredbased royalty amylin net product sales us cppib royalties presented income million million november bms transferred percentage future royalty rights portion onglyza farxiga net product sales royalty pharma transferred rights represent approximately potential future royalties bms entitled products exchange transfer bms receive additional tieredbased royalty onglyza farxiga net product sales royalty pharma presented income earned summarized financial information related astrazeneca alliances follows year ended december dollars millions revenues astrazeneca alliances net product sales alliance revenues total revenues income net amortization deferred income royalties transitional services divestiture gain selected alliance cash flow information deferred income divestiture proceeds selected alliance balance sheet information december dollars millions deferred income services yet performed astrazeneca sanofi bms sanofi codevelopment cocommercialization agreements plavix avaproavalide effective january sanofi assumed essentially worldwide operations alliance exception plavix us puerto rico bms operating partner controlling interest exchange rights transferred sanofi bms receives quarterly royalties january december terminal payment sanofi million end result adoption asc future royalties longer recorded alliance revenues recorded cumulative effect adjustment first quarter corresponding contract asset addition portion terminal payment recorded cumulative effect adjustment first quarter corresponding contract asset royalties received sanofi territory covering americas australia optout markets former development royalties presented alliance revenues million million million royalties attributed territory covering europe asia continue earned territory partnership included equity net income affiliates alliance revenues attributed supply irbesartan api sanofi million summarized financial information related alliance follows year ended december dollars millions revenues sanofi alliances net product sales alliance revenues total revenues payments tofrom sanofi equity net income affiliates noncontrolling interest pretax following summarized financial information interests partnerships sanofi territory covering europe asia consolidated accounted using equity method year ended december dollars millions net sales gross profit net income ono bms principal end customer product sales exclusive right develop manufacture commercialize opdivo worldwide except japan south korea taiwan ono entitled receive royalties north america territories excluding three countries listed subject customary adjustments bms ono jointly develop commercialize opdivo yervoy several bms investigational compounds japan south korea taiwan bms responsible supply products profits losses development costs shared equally combination therapies involving compounds parties otherwise sharing activities involving one partys compounds bms ono also jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulations jointly promoted parties assigned customer accounts bms responsible product supply copromotion fee paid sale made partys assigned customer ono granted bms exclusive license development commercialization ono onos prostaglandin e receptor antagonist bms acquired worldwide rights except japan south korea taiwan added existing collaboration china asean countries ono retained exclusive rights bms paid million ono included rd expense ono eligible receive subsequent clinical regulatory salesbased milestone payments million royalties countries bms exclusive licensing rights summarized financial information related alliance follows year ended december dollars millions revenues ono alliances net product sales alliance revenues total revenues abbvie bms granted exclusive global rights codevelop commercialize empliciti humanized monoclonal antibody treatment multiple myeloma pdl biopharma inc part abbvie abbvie currently participates joint development us commercialization committees bms final decision making authority parties jointly develop product abbvie funds global development costs bms solely responsible supply distribution sales marketing activities principal end customer product sales abbvie shares profits losses us paid tiered royalties outside us bms paid abbvie million certain regulatory milestone events including million approval milestones december abbvie also entitled receive additional million certain regulatory events occur million certain sales thresholds achieved agreement may terminated immediately bms either party material breaches subsequent notice period summarized financial information related alliance follows year ended december dollars millions revenues abbvie alliance net product sales payments tofrom abbvie cost products sold profit sharing fstar alpha october bms acquired exclusive option purchase fstar alpha lead asset fs antiher antibody fragment development treatment breast gastric cancer among welldefined population herpositive patients bms discontinued development fs exercise option resulting iprd charge million included rd expense attributed noncontrolling interest promedior september bms purchased warrant gives bms exclusive right acquire promedior biotechnology company whose lead asset prm developed treatment ipf mf warrant exercisable upon delivery phase ii data following either ipf mf phase ii clinical studies directed promedior upfront payment allocated warrant million included rd expenses remaining million million upfront payment allocated promediors obligation complete phase ii studies amortized expected period phase ii studies allocation determined using level inputs bms obligated pay additional million plus additional aggregate consideration million contingent development regulatory approval milestone payments us europe exercises warrant five prime november bms five prime entered exclusive worldwide licensing collaboration agreement development commercialization five primes csfr antibody program including cabiralizumab currently phase ii development io indications phase ii development pvns five prime responsible completion phase study combining cabiralizumab opdivo potential treatment variety cancers bms responsible development manufacturing commercialization activities five prime may conduct certain studies cost develop cabiralizumab pvns combination internal oncology pipeline assets five prime also retained option copromote us agreement replaces previous clinical collaboration agreement two parties consideration licensing rights bms made upfront payment million included rd expense bms also committed pay billion upon achievement contingent development regulatory milestones well future royalties product approved commercialized reckitt may bms transferred reckitt right sell distribute market several otc brands sold primarily mexico brazil may bms received royalties net sales products exclusively supplied certain products reckitt pursuant supply agreement cost plus markup certain limited assets including marketing authorizations certain employees directly attributed business transferred reckitt start alliance period bms retained ownership assets related business including trademarks covering products bms also granted reckitt option acquire trademarks inventory certain assets exclusively related products end alliance period price determined primarily based upon multiple sales may may april alliance modified provide option reckitt purchase bms manufacturing facility located mexico primarily dedicated products included alliance well related employees july reckitt notified bms exercising option may bms sold business million nonrefundable upfront proceeds million received bms allocated two units accounting including rights transferred reckitt fair value option purchase remaining assets using best estimate selling price elements considering various market factors market factors included analysis estimated excess fair value business potential purchase price option exercised fair value option determined using level inputs included liabilities bms recognized income million decrease fair value option zero due strengthening us dollar local currencies amount allocated rights transferred reckitt amortized alliance revenue contractual term summarized financial information related alliance follows year ended december dollars millions revenues reckitt alliance alliance revenues income net divestiture gain selected alliance cash flow information changes operating assets liabilities divestiture proceeds medicines company february bms transferred medicines company right sell distribute market recothrom global basis two years certain employees directly attributed business certain assets transferred medicines company start alliance period including biologics license application related regulatory assets bms retained assets related recothrom including patents trademarks inventory bms also granted medicines company option acquire patents trademarks inventory certain assets exclusively related recothrom price determined based multiple sales plus cost remaining inventory held bms time medicines company exercised option february acquired business million resulting million divestiture gain valeant october bms transferred pharmaswiss sa whollyowned subsidiary valeant right sell distribute market certain mature brand products europe december bms also granted valeant option acquire trademarks intellectual property exclusively related products price determined based multiple sales valeant exercised option january acquired business million resulting million divestiture gain note acquisitions divestitures licensing arrangements acquisitions acquisitions evaluated determine whether business asset group assets following transactions accounted asset acquisitions since determined business term defined asc business combinations primarily significant processes acquired result amounts allocated lead investigational compounds expensed capitalized consideration transaction allocated follows contingent dollars millions year upfront payment rd expense deferred tax assetsa consideration ifmb cormorant padlock cardioxyl flexusc relates net operating loss tax credit carryforwards b includes million certain negotiation rights collaborate license acquire nlrp antagonist program newly formed entity established former shareholders ifm c includes million acquisition costs ifm bms acquired outstanding shares ifm private biotechnology company focused developing therapies modulate novel targets innate immune system treat cancer autoimmunity inflammatory diseases acquisition provided bms full rights ifm 's preclinical sting nlrp agonist programs focused enhancing innate immune response treating cancer contingent consideration includes development regulatory salesbased milestone payments bms may pay million additional contingent milestones subsequent products selected ifm 's preclinical sting nlrp agonist programs included contingent consideration amount table cormorant bms acquired outstanding shares cormorant private pharmaceutical company focused development therapies cancer rare diseases acquisition provided bms full rights cormorant 's lead candidate humaxil phase iii monoclonal antibody represents potentially complementary immunooncology mechanism action tcell directed antibodies costimulatory molecules contingent consideration includes development regulatory milestone payments padlock bms acquired outstanding shares padlock private biotechnology company dedicated creating new medicines treat destructive autoimmune diseases acquisition provided bms full rights padlocks pad inhibitor discovery program focused development potentially transformational treatment approaches patients rheumatoid arthritis padlocks pad discovery program may additional utility treating systemic lupus erythematosus autoimmune diseases contingent consideration includes development regulatory milestone payments cardioxyl bms acquired outstanding shares cardioxyl private biotechnology company focused discovery development novel therapeutic agents cardiovascular disease acquisition provided bms full rights cxl nitroxyl prodrug phase ii development acute decompensated heart failure contingent consideration includes development regulatory salesbased milestone payments million included rd expense following commencement phase ii clinical study flexus bms acquired outstanding shares flexus private biotechnology company focused discovery development novel anticancer therapeutics acquisition provided bms full rights f preclinical small molecule idoinhibitor targeted immunotherapy addition bms acquired flexus 's idotdo discovery program includes idoselective idotdo dual tdoselective compounds contingent consideration includes development regulatory milestone payments million million included rd expense respectively following commencement phase phase ii phase iii clinical studies divestitures proceedsa divestiture gains losses royalty income dollars millions investigational hiv medicines otc brands reckitt diabetes erbitux recothrom mature brand products valeant ixempra includes royalties received subsequent related sale asset business sk biotek bms sold small molecule active pharmaceutical ingredient manufacturing operations swords ireland sk biotek approximately million subject certain adjustments initial proceeds million received first quarter transaction accounted sale business divestiture includes transfer facility majority employees site inventories certain thirdparty contract manufacturing obligations assets reduced estimated relative fair value considering purchase price resulting impairment charge million included cost products sold sk biotek provide certain manufacturing services bms viiv healthcare bms sold investigational hiv medicines business consisting number rd programs different stages discovery development viiv healthcare bms received million also entitled receive viiv healthcare contingent development regulatory milestone payments billion salesbased milestone payments billion future tiered royalties bms earned transitional fees million million certain rd services respectively divestitures refer note alliances discussion divestiture transactions reckitt lilly medicines company valeant astrazeneca revenues pretax earnings related divestitures material excluding divestiture gains impairment charges assets heldforsale bms agreed sell rd facility wallingford connecticut transaction expected close first quarter accounted sale asset asset accounted heldforsale december reduced estimated relative fair value resulting impairment charge million included rd expense licensing arrangements halozyme bms halozyme entered global collaboration license agreement develop subcutaneously administered bms io medicines using halozyme 's enhanze drugdelivery technology technology may allow rapid delivery large volume injectable medications subcutaneous delivery bms paid million halozyme access technology included rd expense bms designated multiple io targets including pd develop using enhanze technology option select additional targets within five years effective date maximum targets bms may pay additional million achieved contingent development regulatory salesbased milestones nominated collaboration targets additional milestone payments combination products future royalties sales products using enhanze technology cytomx bms expanded strategic collaboration cytomx discover novel therapies using cytomxs proprietary probody platform part original may collaboration discover develop commercialize probody therapeutics bms selected four oncology targets including ctla pursuant expanded agreement cytomx granted bms exclusive worldwide rights develop commercialize probody therapeutics eight additional targets bms paid cytomx million rights initial four targets expensed rd prior bms paid million cytomx access additional targets included rd expense bms also reimburse cytomx certain research costs collaboration period pay contingent development regulatory sales based milestones million achieved collaboration target future royalties biogen bms outlicensed biogen exclusive rights develop commercialize bms antietau compound development progressive supranuclear palsy biogen paid million bms included income bms also entitled contingent development regulatory sales based milestone payments million achieved future royalties bms originally acquired rights compound acquisition ipierian biogen assumed bmss remaining obligations former stockholders ipierian roche bms outlicensed roche exclusive rights develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy roche paid million bms included income bms also entitled contingent development regulatory milestone payments million achieved future royalties note income net income net includes year ended december dollars millions interest expense investment income provision restructuring litigation settlements equity net income affiliates divestiture gains royalties licensing income transition service fees pension charges intangible asset impairment equity investment impairment written option adjustment loss debt redemption income net litigation settlements includes bms 's share patentinfringement settlement million related merck 's pd antibody keytruda million contractual dispute related license royalties licensing income includes upfront licensing fees million biogen roche transition service fees primarily related divestiture diabetes investigational hiv medicines businesses written option adjustment includes change fair value written option liability attributed reckitt alliance includes unrealized foreign exchange loss million resulting remeasurement bolivardenominated cash monetary balances bmss whollyowned subsidiary venezuela december note restructuring october company announced restructuring plan evolve streamline operating model expects incur charges connection employee workforce reductions early site exits majority charges expected incurred range billion billion consist employee termination benefit costs contract termination costs accelerated depreciation impairment charges site exit costs cash outlays connection actions expected approximately total charges charges approximately million recognized actions since announcement including impairment charge small molecule manufacturing operation swords ireland restructuring charges recognized upon meeting certain criteria including finalization committed plans reliable estimates discussions local works councils certain markets restructuring charges addition actions recognized prior primarily related specialty care transformation initiatives designed create simplified organization across functions geographic markets addition accelerated depreciation charges incurred connection expected early exits small molecule manufacturing site cruiserath ireland rd facility wallingford connecticut refer note acquisitions divestitures licensing arrangements information employee workforce reductions approximately following tables summarize charges activity related restructuring actions year ended december dollars millions employee termination costs termination costs provision restructuring accelerated depreciation asset impairments shutdown costs total charges year ended december dollars millions cost products sold marketing selling administrative research development income net total charges year ended december dollars millions liability january charges change estimates provision restructuring foreign currency translation spending liability december note income taxes provisionbenefit income taxes consisted year ended december dollars millions current us nonus total current deferred us nonus total deferred total provision effective tax rate reconciliation effective taxbenefit rate us statutory federal income tax rate earnings income taxes dollars millions earningsloss income taxes us nonus total us statutory rate deemed repatriation transition tax deferred tax remeasurement foreign tax effect certain operations ireland puerto rico switzerland us federal valuation allowance release us federal state foreign contingent tax matters us federal research based credits goodwill allocated divestitures us branded prescription drug fee nondeductible rd charges puerto rico excise tax domestic manufacturing deduction state local taxes net valuation allowance foreign new tax reform legislation us enacted december known tax cuts jobs act act act moves worldwide tax system quasiterritorial tax system comprises broad complex changes us tax code including limited reducing us tax rate adding deemed repatriation transition tax certain foreign earnings profits generally eliminating us federal income taxes dividends foreign subsidiaries including certain income controlled foreign companies us taxable income creating new minimum tax referred base erosion antiabuse income tax limiting certain researchbased credits eliminating domestic manufacturing deduction although many aspects act effective additional tax expense billion recognized fourth quarter upon enactment act additional expense included billion onetime deemed repatriation transition tax previously untaxed post foreign earnings profits including related tax reserves earnings effectively taxed rate extent specified foreign corporations held cash certain assets rate remaining earnings profits remaining additional tax expense included adjustment measure net deferred tax assets new us tax rate accounting reduction deferred tax assets tax rate complete tax charge deemed repatriation tax incomplete recorded provisional amount able make reasonable estimate tax provisional amounts may change completed upon finalizing untaxed post foreign earnings profits related cash certain eligible assets specified foreign corporations provisional amounts may also change additional guidance relevant tax code released earnings certain manufacturing operations low tax jurisdictions switzerland ireland puerto rico indefinitely reinvested prior enactment act bms operates favorable tax grant puerto rico scheduled expire prior result transition tax act company longer indefinitely reinvested respect undistributed earnings foreign subsidiaries provided deferred tax liability foreign state income withholding tax would apply company remains indefinitely reinvested respect financial statement basis excess tax basis foreign subsidiaries determination deferred tax liability respect basis difference practicable valuation allowances attributed capital loss carryforwards released following divestiture recothrom ixempra mature brands goodwill allocated business divestitures well us branded prescription drug fee deductible tax purposes rd charges primarily acquisition related milestone payments former shareholders deductible tax purposes include flexus cardioxyl ifm flexus padlock cormorant flexus cardioxyl puerto rico imposes excise tax gross company purchase price goods sold manufacturer puerto rico excise tax recognized cost products sold intraentity sale occurs us income tax purposes excise tax deductible results foreign tax credits generally recognized provision income taxes excise tax incurred increased manufacturing activities opdivo resulted higher domestic manufacturing deduction compared deferred taxes valuation allowance components current noncurrent deferred income tax assetsliabilities follows december dollars millions deferred tax assets foreign net operating loss carryforwards state net operating loss credit carryforwards us federal net operating loss credit carryforwards deferred income milestone payments license fees pension postretirement benefits intercompany profit inventory items foreign deferred tax assets sharebased compensation internal transfer intellectual property total deferred tax assets valuation allowance deferred tax assets net valuation allowance deferred tax liabilities depreciation acquired intangible assets goodwill total deferred tax liabilities deferred tax assets net recognized deferred income taxes noncurrent income taxes payable noncurrent total adoption amended guidance intraentity transfers assets inventory resulted net reductions prepaid deferred tax assets pertaining pre internal transfers intellectual property million adjusted retained earnings cumulative effect accounting change additionally amended guidance sharebased payment transactions adopted net excess tax benefits million recognized prospectively reduction tax expense rather capital excess par value stock tax benefit realized result stock related compensation credited capital excess par value stock million million adoption amended guidance items reduced effective tax rate year ended december refer note basis presentation recently issued accounting standards information us federal net operating loss carryforwards million december carryforwards acquired result certain acquisitions subject limitations section internal revenue code net operating loss carryforwards expire varying amounts beginning foreign state net operating loss carryforwards expire varying amounts beginning certain amounts unlimited lives december valuation allowance million established following items million primarily foreign net operating loss tax credit carryforwards million state deferred tax assets including net operating loss tax credit carryforwards million us federal net operating loss carryforwards million us federal deferred tax assets changes valuation allowance follows year ended december dollars millions balance beginning year provision utilization foreign currency translation acquisitions non us rate change balance end year income tax payments million billion million business conducted various countries throughout world subject tax numerous jurisdictions significant number tax returns filed subject examination various federal state local tax authorities tax examinations often complex tax authorities may disagree treatment items reported requiring several years resolve liabilities established possible assessments tax authorities resulting known tax exposures including limited transfer pricing matters tax credit deductibility certain expenses deemed repatriation transition tax liabilities represent reasonable provision taxes ultimately expected paid may need adjusted time information becomes known effect changes estimates related contingent tax liabilities included effective tax rate reconciliation reconciliation beginning ending amount gross unrecognized tax benefits follows year ended december dollars millions balance beginning year gross additions tax positions related current year gross additions tax positions related prior years gross additions tax positions assumed acquisitions gross reductions tax positions related prior years settlements reductions tax positions related lapse statute cumulative translation adjustment balance end year additional information regarding unrecognized tax benefits follows year ended december dollars millions unrecognized tax benefits recognized would impact effective tax rate accrued interest accrued penalties accrued interest penalties payable unrecognized tax benefits included either current noncurrent income taxes payable interest penalties related unrecognized tax benefits included income tax expense bms currently examination number tax authorities proposed considering proposing material adjustments tax positions issues transfer pricing certain tax credits deductibility certain expenses reasonably possible new issues raised tax authorities may require adjustments amount unrecognized tax benefits however estimate adjustments reasonably made time also reasonably possible total amount unrecognized tax benefits december could decrease range approximately million million next twelve months result settlement certain tax audits events expected change unrecognized tax benefits may result payment additional taxes adjustment certain deferred taxes andor recognition tax benefits reasonably possible new issues raised tax authorities may increase unrecognized tax benefits however estimate increases reasonably made time bms believes adequately provided open tax years tax jurisdiction following summary major tax jurisdictions tax authorities may assert additional taxes based upon tax years currently audit subsequent years likely audited us canada france germany italy mexico note earnings per share year ended december amounts millions except per share data net earnings attributable bms used basic diluted eps calculation weightedaverage common shares outstanding basic incremental shares attributable sharebased compensation plans weightedaverage common shares outstanding diluted earnings per share basic earnings per share diluted note financial instruments fair value measurements financial instruments include cash cash equivalents marketable securities accounts receivable payable debt instruments derivatives changes exchange rates interest rates create exposure market risk certain derivative financial instruments used available costeffective basis hedge underlying economic exposure instruments qualify cash flow net investment fair value hedges upon meeting certain criteria including effectiveness offsetting hedged exposures changes fair value derivatives qualify hedge accounting recognized earnings occur derivative financial instruments used trading purposes financial instruments subject counterparty credit risk considered part overall fair value measurement counterparty credit risk monitored ongoing basis mitigated limiting amounts outstanding individual counterparty utilizing conventional derivative financial instruments entering agreements counterparties meet high credit quality standards consolidated financial statements would materially impacted counterparty failed perform according terms agreement collateral required party whether derivatives asset liability position terms agreements fair value measurements fair value financial instruments classified one following categories level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets additionally certain corporate debt securities utilize thirdparty matrix pricing model using significant inputs corroborated market data substantially full term assets equity fixed income funds primarily invested publicly traded securities valued respective net asset value underlying investments level derivative instruments valued using libor yield curves less credit valuation adjustments observable forward foreign exchange rates reporting date valuations derivative contracts may fluctuate considerably volatility underlying foreign currencies underlying interest rates driven market conditions duration contract level unobservable inputs used little market data available level financial assets liabilities december financial assets liabilities measured fair value recurring basis summarized december december dollars millions level level level level cash cash equivalents money market securities marketable securities certificates deposit commercial paper corporate debt securities equity funds fixed income funds derivative assets equity investments derivative liabilities equity investments measured fair value year end excluded table limited partnerships equity method investments million million equity investments without readily determinable fair values million million amounts included assets availableforsale securities following table summarizes availableforsale securities december december gross unrealized gross unrealized amortized amortized dollars millions cost gains losses fair value cost gains losses fair value certificates deposit commercial paper corporate debt securities equity investments financial assets measured using fair value option equity fixed income fundsa total december december dollars millions current marketable securities noncurrent marketable securitiesb assetsc total fair value option financial assets elected investments equity fixed income funds included current marketable securities changes fair value significant ball noncurrent marketable securities mature within five years december cincludes equity investments qualifying hedges nonqualifying derivatives following summarizes fair value outstanding derivatives december december asseta liabilityb asseta liabilityb dollars millions notional fair value notional fair value notional fair value notional fair value derivatives designated hedging instruments interest rate swap contracts forward starting interest rate swap contracts foreign currency forward contracts derivatives designated hedging instruments foreign currency forward contracts aincluded prepaid expenses assets bincluded accrued liabilities pension liabilities cash flow hedges foreign currency forward contracts used hedge certain forecasted intercompany inventory purchase transactions certain foreign currency transactions effective portion changes fair value contracts designated cash flow hedges temporarily reported accumulated comprehensive loss included earnings hedged item affects earnings net gains foreign currency forward contracts expected reclassified net earnings primarily included cost products sold within next two years notional amount outstanding foreign currency forward contracts primarily attributed euro million japanese yen million december bms entered million forward starting interest rate swap contracts maturing march hedge variability probable forecasted interest expense associated potential future issuances debt bms terminated forward starting interest rate swap contracts proceeds related gain material contracts designated cash flow hedges effective portion fair value changes included comprehensive income earnings impact related discontinued cash flow hedges hedge ineffectiveness significant periods presented cash flow hedge accounting discontinued forecasted transaction longer probable occurring within days originally forecasted date hedge longer effective assessments determine whether derivatives designated qualifying hedges highly effective offsetting changes cash flows hedged items performed inception quarterly basis net investment hedges nonus dollar borrowings million million december designated hedge foreign currency exposures net investment certain foreign affiliates borrowings designated net investment hedges recognized long term debt effective portion foreign exchange loss remeasurement euro debt million gain million million respectively recorded foreign currency translation component accumulated comprehensive loss related offset longterm debt fair value hedges fixedtofloating interest rate swap contracts designated fair value hedges used interest rate risk management strategy create appropriate balance fixed floating rate debt contracts underlying debt hedged benchmark risk recorded fair value effective interest rate contracts onemonth libor december plus interest rate spread ranging underlying swap terminated prior maturity fair value basis adjustment underlying debt instrument amortized reduction interest expense remaining life debt notional amount fixedtofloating interest rate swap contracts executed million notional amount fixedtofloating interest rate swap contracts terminated million million generating proceeds million million including accrued interest additional contracts terminated connection debt redemptions debt obligations shortterm debt obligations include december dollars millions commercial paper nonus shortterm borrowings current portion longterm debt total average amount commercial paper outstanding million weightedaverage interest rate maximum amount commercial paper outstanding billion million outstanding borrowings december commercial paper borrowings longterm debt current portion longterm debt includes december dollars millions principal value notes due notes due notes due notes due notes due notes due euro notes due notes due notes due euro notes due notes due notes due notes due notes due notes due maturing subtotal adjustments principal value fair value interest rate swap contracts unamortized basis adjustment swap terminations unamortized bond discounts issuance costs total current portion longterm debt longterm debt fair value longterm debt billion billion december respectively estimated using level inputs based upon quoted market prices similar debt instruments fair value shortterm borrowings approximates carrying value due short maturities debt instruments senior unsecured notes issued registered public offerings notes rank equally right payment bms 's existing future senior unsecured indebtedness redeemable whole part time predetermined redemption price bms also terminated forward starting interest rate swap contracts entered resulting unrealized loss comprehensive income following table summarizes issuance longterm debt obligations none amounts millions us dollars euro us dollars principal value notes due euro notes due notes due euro notes due total proceeds net discount deferred loan issuance costs forward starting interest rate swap contracts terminated notional amount realized gain unrealized loss bms repaid million notes maturity following summarizes debt redemption activity none dollars millions principal amount carrying value debt redemption price notional amount interest rate swap contracts terminated interest rate swap termination payments loss debt redemptiona aincluding acceleration debt issuance costs loss interest rate lock contract related fees interest payments million million million net amounts received interest rate swap contracts currently three separate revolving credit facilities totaling billion syndicate lenders facilities provide customary terms conditions financial covenants day billion facility expires march two billion facilities extended october july two billion fiveyear facilities extendable annually one year anniversary date consent lenders borrowings outstanding revolving credit facility december available financial guarantees provided form standby letters credit performance bonds million december standby letters credit issued financial institutions support guarantees various obligations performance bonds issued support range ongoing operating activities including sale products hospitals foreign ministries health bonds customs duties value added tax guarantees related miscellaneous legal actions significant majority outstanding financial guarantees expire within year expected funded note receivables december dollars millions trade receivables less chargebacks cash discounts less bad debt allowances net trade receivables alliance receivables prepaid refundable income taxes royalties vat receivables nonus receivables sold nonrecourse basis million million million aggregate receivables three pharmaceutical wholesalers us represented total trade receivables december respectively changes allowances bad debt chargebacks cash discounts follows year ended december dollars millions balance beginning year provision utilization balance end year note inventories december dollars millions finished goods work process raw packaging materials inventories inventories assets assets include inventory expected remain hand beyond one year periods note property plant equipment leases december dollars millions land buildings machinery equipment fixtures construction progress gross property plant equipment less accumulated depreciation property plant equipment depreciation expense million million million gross property plant equipment million million net accumulated depreciation reclassified assets heldforsale december result pending sale rd facility wallingford connecticut refer note acquisitions divestitures licensing arrangements additional information annual minimum rental commitments noncancelable operating leases primarily real estate motor vehicles approximately million next five years aggregate million thereafter operating lease expense approximately million million million sublease income capital lease obligations material periods presented note goodwill intangible assets december estimated dollars millions useful lives goodwill intangible assets licenses years developed technology rights years capitalized software years iprd gross intangible assets less accumulated amortization total intangible assets amortization expense intangible assets million million million future annual amortization expense intangible assets expected approximately million million million million million intangible asset impairment charges million million million million iprd charge recognized attributed noncontrolling interest bms declined exercise option purchase fstar alpha million iprd impairment charge recognized bms lpa antagonist phase ii development treatment ipf full writeoff required considering occurrence certain adverse events voluntary suspension study internal assessment indicating significantly lower likelihood regulatory commercial success bms acquired bms acquisition amira pharmaceuticals inc note accrued liabilities december dollars millions rebates returns employee compensation benefits research development dividends royalties branded prescription drug fee restructuring pension postretirement benefits litigation settlements accrued liabilities note equity common stock capital treasury stock excess par value accumulated retained noncontrolling dollars shares millions shares par value stock comprehensive loss earnings shares cost interest balance january net earnings comprehensive loss cash dividends stock compensation debt conversion distributions balance december net earnings comprehensive loss cash dividends stock repurchase program stock compensation distributions balance december accounting change cumulative effecta adjusted balance january net earnings comprehensive income cash dividends stock repurchase program stock compensation variable interest entity distributions balance december refer note accounting policies recently issued accounting standards additional information bms stock repurchase program authorized board directors allowing repurchases open market private transactions including plans established accordance rule b securities exchange act stock repurchase program expiration date may suspended discontinued time treasury stock recognized cost reacquire shares shares issued treasury recognized utilizing firstin firstout method bms repurchased shares rule b open market purchases accelerated share repurchase agreements bms completed accelerated share repurchase agreements repurchased approximately million shares company 's common stock aggregate billion agreements funded combination debt cash components comprehensive incomeloss follows year ended december dollars millions pretax tax tax pretax tax tax pretax tax tax derivatives qualifying cash flow hedges unrealized gainslosses reclassified net earningsa derivatives qualifying cash flow hedges pension postretirement benefits actuarial gainslosses amortizationb settlementsc pension postretirement benefits availableforsale securities unrealized gainslosses realized gainslossesc availableforsale securities foreign currency translation total comprehensive incomeloss included cost products sold b included cost products sold research development marketing selling administrative expenses c included income net accumulated balances related component comprehensive loss net taxes follows december dollars millions derivatives qualifying cash flow hedges pension postretirement benefits availableforsale securities foreign currency translation accumulated comprehensive loss note pension postretirement benefit plans bms sponsors defined benefit pension plans defined contribution plans termination indemnity plans regular fulltime employees principal defined benefit pension plan bristolmyers squibb retirement income plan covering us employees representing approximately consolidated pension plan assets obligations future benefits related service plan eliminated bms contributes least minimum amount required erisa plan benefits based primarily participants years credited service final average compensation plan assets consist principally equity fixedincome securities net periodic benefit costcredit defined benefit pension plans includes dollars millions service cost benefits earned year interest cost projected benefit obligation expected return plan assets amortization prior service credits amortization net actuarial loss curtailments settlements special termination benefits net periodic benefit costcredit pension settlement charges recognized determining annual lump sum payments exceed annual interest service costs certain pension plans including primary us pension plan changes defined benefit pension plan obligations assets funded status amounts recognized consolidated balance sheets follows dollars millions benefit obligations beginning year service costbenefits earned year interest cost settlements actuarial gainslosses benefits paid foreign currency benefit obligations end year fair value plan assets beginning year actual return plan assets employer contributions settlements benefits paid foreign currency fair value plan assets end year funded status assetsliabilities recognized assets accrued liabilities pension liabilities funded status recognized accumulated comprehensive loss net actuarial losses prior service credit total accumulated benefit obligation defined benefit pension plans billion billion december respectively additional information related pension plans follows dollars millions pension plans projected benefit obligations excess plan assets projected benefit obligation fair value plan assets pension plans accumulated benefit obligations excess plan assets accumulated benefit obligation fair value plan assets actuarial assumptions weightedaverage assumptions used determine defined benefit pension plan obligations december follows discount rate rate compensation increase weightedaverage actuarial assumptions used determine defined benefit pension plan net periodic benefit creditcost years ended december follows discount rate expected longterm return plan assets rate compensation increase yield high quality corporate bonds matching duration benefit obligations used determining discount rate citi pension discount curve used developing discount rate us plans expected return plan assets determined using expected rate return calculated value assets referred marketrelated value approximated fair value plan assets december differences assumed actual returns amortized marketrelated value straightline basis threeyear period several factors considered developing expected return plan assets including longterm historical returns input external advisors individual asset class return forecasts developed based upon market conditions example priceearnings levels yields longterm growth expectations expected longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualized returns us pension plans follows years years years actuarial gains losses resulted changes actuarial assumptions changes discount rate revised mortality rates differences assumed actual experience differences actual expected return plan assets gains losses amortized life expectancy plan participants us plans years expected remaining service periods plans extent exceed higher marketrelated value projected benefit obligation respective plan amortization net actuarial loss prior service credit expected approximately million periodic benefit cost credit included cost products sold research development marketing selling administrative expenses except curtailments settlements special termination benefits included expenses postretirement benefit plans comprehensive medical group life benefits provided substantially us retirees electing participate comprehensive medical group life plans lesser extent certain benefits nonus employees medical plan contributory contributions adjusted periodically vary date retirement life insurance plan noncontributory plan assets consist principally equity fixedincome securities postretirement benefit plan obligations million million december respectively fair value plan assets million million december respectively weightedaverage discount rate used determine benefit obligations december respectively net periodic benefit credits material plan assets fair value pension postretirement plan assets asset category december follows december december dollars millions level level level total level level level total plan assets equity securities equity funds fixed income funds corporate debt securities us treasury agency securities shortterm investment funds insurance contracts cash cash equivalents plan assets subject leveling plan assets measured nav practical expedient equity funds venture capital limited partnerships total plan assets measured nav practical expedient net plan assets investment valuation policies per investment class follows level inputs utilize unadjusted quoted prices active markets accessible measurement date identical assets liabilities fair value hierarchy provides highest priority level inputs instruments include equity securities equity funds fixed income funds publicly traded national securities exchange cash cash equivalents cash cash equivalents highly liquid investments original maturities three months less time purchase recognized cost approximates fair value pending trade sales purchases included cash cash equivalents final settlement level inputs utilize observable prices similar instruments quoted prices identical similar instruments nonactive markets observable inputs corroborated market data substantially full term assets liabilities equity funds fixed income funds shortterm investment funds classified level within fair value hierarchy valued net asset value shares held year end represents fair value corporate debt securities us treasury agency securities classified level within fair value hierarchy valued utilizing observable prices similar instruments quoted prices identical similar instruments markets active level unobservable inputs used little market data available insurance contracts held certain foreign pension plans carried contract value approximates estimated fair value based fair value underlying investment insurance company venture capital limited partnership investments typically redeemable distributions upon liquidation underlying assets significant unfunded commitments investments essentially liquidations expected occur remaining investments using practical expedient redeemable weekly monthly basis investment strategy maximize return maintaining appropriate level risk provide sufficient liquidity benefit obligations plan expenses target asset allocation public equity international global us private equity longduration fixed income maintained us pension plans investments diversified within three major asset categories approximately us pension plans equity investments actively managed bms common stock represents less plan assets december contributions estimated future benefit payments contributions pension plans million million million expected approximately million estimated annual future benefit payments including lump sum payments range approximately million million next five years aggregate billion subsequent five year period savings plans principal defined contribution plan bristolmyers squibb savings investment program contribution based employee contributions level company match expense attributed defined contribution plans us approximately million note employee stock benefit plans may shareholders approved plan replaced stock incentive plan plan provides million shares authorized grants plus shares outstanding awards plan february expire forfeited canceled withheld satisfy tax withholding obligations december million shares available award shares issued treasury stock satisfy obligations plan executive officers key employees may granted options purchase common stock less market price date option granted options generally become exercisable ratably four years maximum term ten years plan provides granting stock appreciation rights whereby grantee may surrender exercisable rights receive common stock andor cash measured excess market price common stock option exercise price company granted stock options stock appreciation rights since restricted stock units may granted key employees subject restrictions continuous employment generally vesting occurs ratably four year period grant date stock unit right receive stock end specified vesting period voting rights market share units granted executives vesting conditioned upon continuous employment vesting date payout factor least share price award date payout factor share price vesting date divided share price award date maximum share price used payout factor calculated using average closing prices grant vest date nine trading days immediately preceding grant vest date vesting occurs ratably four years performance share units granted executives three year cycle granted target number units subject adjustment number shares issued performance share units vest determined based achievement performance goals based company 's threeyear total shareholder return relative peer group companies vesting conditioned upon continuous employment occurs third anniversary grant date stockbased compensation expense awards ultimately expected vest recognized vesting period forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates information related stockbased compensation benefits follows years ended december dollars millions restricted stock units market share units performance share units total stockbased compensation expense income tax benefit stock options restricted stock units market share units performance share units weighted number weighted number weighted number weighted number average average average average options exercise price nonvested grantdate nonvested grantdate nonvested grantdate shares millions outstanding shares awards fair value awards fair value awards fair value balance january granted releasedexercised adjustments actual payout forfeitedcanceled balance december vested expected vest restricted market performance dollars millions stock units share units share units unrecognized compensation cost expected weightedaverage period years compensation cost recognized amounts millions except per share data weightedaverage grant date fair value per share restricted stock units market share units performance share units fair value awards vested restricted stock units market share units performance share units total intrinsic value stock options exercised fair value restricted stock units market share units performance share units approximates closing trading price bms 's common stock grant date adjusting units eligible accrued dividends addition fair value market share units performance share units considers probability satisfying payout factor total shareholder return respectively following table summarizes significant ranges outstanding exercisable options december options outstanding exercisable number weightedaverage weightedaverage aggregate outstanding exercisable remaining contractual exercise price intrinsic value range exercise prices millions life years per share millions aggregate intrinsic value preceding table represents total pretax intrinsic value based closing stock price december note legal proceedings contingencies company certain subsidiaries involved various lawsuits claims government investigations legal proceedings arise ordinary course business claims proceedings involve various types parties including governments competitors customers suppliers service providers licensees employees shareholders among others resolution matters often develops long period time expectations change result new findings rulings appeals settlement arrangements company recognizes accruals contingencies probable liability incurred amount loss reasonably estimated matters involve patent infringement antitrust securities pricing sales marketing practices environmental commercial contractual rights licensing obligations health safety matters consumer fraud employment matters product liability insurance coverage legal proceedings material company believes could become material described although company believes substantial defenses matters assurance increase scope pending matters future lawsuits claims government investigations legal proceedings material unless otherwise noted company unable assess outcome respective litigation able provide estimated range potential loss furthermore failure enforce patent rights would likely result substantial decreases respective product revenues generic competition intellectual property plavix australia previously disclosed sanofi notified august genrx proprietary limited genrx obtained regulatory approval application clopidogrel bisulfate mg tablets australia genrx formerly subsidiary apotex inc apotex since changed name apotex august apotex filed application federal court australia federal court seeking revocation sanofis australian patent case nsd sanofi filed counterclaims infringement sought injunction september federal court granted sanofis injunction subsidiary company subsequently added party proceedings february second company spirit pharmaceuticals pty ltd also filed revocation suit patent case consolidated apotex case trial occurred april august federal court australia held claims patent covering clopidogrel bisulfate hydrochloride hydrobromide taurocholate salts valid federal court also held process claims pharmaceutical composition claims claim directed clopidogrel pharmaceutically acceptable salts invalid company sanofi filed notices appeal full court federal court australia full court appealing holding invalidity claim covering clopidogrel pharmaceutically acceptable salts process claims pharmaceutical composition claims stayed federal courts ruling apotex filed notice appeal appealing holding validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claims hearing appeals occurred february september full court held claims patent invalid november company sanofi applied high court australia high court special leave appeal judgment full court march high court denied company sanofis request hear appeal full court decision case remanded federal court proceedings related damages sought apotex company apotex settled apotex case case dismissed australian government intervened matter seeking maximum damages million aud million plus interest would split company sanofi alleged losses experienced paying higher price branded plavix period injunction place company sanofi disputed australian government entitled damages australian government 's claim still pending trial concluded september company expecting decision sprycel european union may apotex actavis group ptc ehf generics uk limited mylan unnamed company filed oppositions epo seeking revocation european patent patent covering dasatinib active ingredient sprycel patent scheduled expire april excluding potential term extensions january opposition division epo revoked patent may company appealed epos decision epo board appeal february epo board appeal upheld opposition division 's decision revoked patent orphan drug exclusivity data exclusivity sprycel eu expired november epo board appeal 's decision affect validity sprycel patents within outside europe including different patents cover monohydrate form dasatinib use dasatinib treat cml additionally february epo board appeal reversed remanded invalidity decision european patent claim use dasatinib treat cml epo 's opposition division revoked october company intends take appropriate legal actions protect sprycel may experience decline european revenues event generic dasatinib product enters market antipd antibody patent oppositions litigation september danafarber cancer institute danafarber filed complaint massachusetts federal court seeking correct inventorship five related us patents directed methods treating cancer using pd pdl antibodies specifically danafarber seeking add two scientists inventors patents october pfizer allowed intervene case alleging one scientists identified danafarber employed company eventually acquired pfizer relevant period adverse decision litigation would result monetary liability company could decrease potential future licensing revenue patents eliquis patent litigation us twentyfive generic companies sent company paragraphiv certification letters informing company filed abbreviated new drug applications andas seeking approval generic versions eliquis result two eliquis patents listed fda orange book challenged composition matter patent claiming apixaban specifically formulation patent april company along partner pfizer initiated patent lawsuits hatchwaxman act generic filers federal district courts delaware west virginia august united states patent trademark office granted patent term restoration composition matter patent thereby restoring term eliquis composition matter patent companys basis projected loe february november company settled lawsuits several anda filers february settlements affect companys projected loe eliquis pricing sales promotional practices litigation plavix state attorneys general lawsuits company certain affiliates sanofi defendants consumer protection andor false advertising actions brought several states relating sales promotion plavix product liability litigation company party various product liability lawsuits plaintiffs cases seek damages relief various grounds alleged personal injury economic loss previously disclosed addition lawsuits company also faces unfiled claims involving products plavix previously disclosed company certain affiliates sanofi defendants number individual lawsuits various state federal courts claiming personal injury damage allegedly sustained using plavix claims involving injury plaintiffs well claims spouses andor beneficiaries filed state federal courts various states including california new jersey delaware new york february judicial panel multidistrict litigation granted company sanofis motion establish multidistrict litigation mdl coordinate federal pretrial proceedings plavix product liability related cases new jersey federal court following united states supreme courts june reversal california supreme court decision held california state courts exercise personal jurisdiction claims noncalifornia residents outofstate resident plaintiffs ' claims including spouses beneficiaries previously pending california state court dismissed number california non resident plaintiffs claims may refiled federal court company filed summary judgment motions remaining cases law firms representing majority remaining cases represented various courts withdraw discontinue cases resolution remaining lawsuits expected material impact company byetta amylin former subsidiary company lilly codefendants product liability litigation related byetta date separate lawsuits pending behalf approximately active plaintiffs including pending settlements include injury plaintiffs well claims spouses andor beneficiaries various courts us previously reported company agreed resolve certain claims claims process dismissed majority cases brought individuals allege personal injury sustained using byetta primarily pancreatic cancer pancreatitis cases claiming alleged wrongful death majority cases pending federal court san diego mdl coordinated proceeding california superior court los angeles jccp november defendants ' motion summary judgment based federal preemption granted mdl jccp plaintiffs mdl appealed us court appeals ninth circuit november ninth circuit reversed mdl summary judgment order remanded case proceedings jccp plaintiffs appealed california court appeal appeal remains pending amylin product liability insurance covering substantial number claims involving byetta additional liability amylin respect byetta expected shared company astrazeneca abilify company otsuka codefendants product liability litigation related abilify plaintiffs allege abilify caused engage compulsive gambling impulse control disorders cases filed state federal courts several additional cases pending canada judicial panel multidistrict litigation consolidated federal court cases pretrial purposes united states district court northern district florida first mdl trial currently scheduled take place june eliquis company pfizer codefendants product liability litigation related eliquis plaintiffs assert claims including claims wrongful death result bleeding allege caused use eliquis majority claims pending mdl united states district court southern district new york state court delaware january cases pending courts united states one pending canada cases dismissed prejudice mdl plaintiffs appealed dismissed cases second circuit court appeals shareholder derivative litigation since december three shareholder derivative lawsuits filed new york state court certain officers directors company plaintiffs allege among things breaches fiduciary duty surrounding companys previously disclosed october civil settlement securities exchange commission alleged foreign corrupt practices act violations china company agreed payment approximately million disgorgement penalties interest october three lawsuits dismissed company received notice appeal one dismissed lawsuits securities litigation february company became aware putative class action complaint joseph giugno v bristolmyers squibb co et al filed us district northern district california company companys chief executive officer giovanni caforio companys chief financial officer charles bancroft certain former current executives company complaint alleges violations securities laws companys disclosures related checkmate clinical trial lung cancer company intends defend vigorously litigation government investigations like pharmaceutical companies company certain subsidiaries subject extensive regulation national state local government agencies us countries bms operates result company time time subject various governmental inquiries investigations possible criminal charges substantial fines andor civil penalties could result government investigations environmental proceedings previously reported company party several environmental proceedings matters responsible various state federal foreign laws including cercla certain costs investigating andor remediating contamination resulting past industrial activity companys current former sites waste disposal reprocessing facilities operated third parties cercla matters respect cercla matters company responsible various state federal foreign laws company typically estimates potential costs based information obtained us environmental protection agency counterpart state foreign agency andor studies prepared independent consultants including total estimated costs site expected costsharing potentially responsible parties company accrues liabilities probable reasonably estimable company estimated share future costs sites million december represents sum best estimates best estimate reasonably made estimates minimal probable amount among range costs without taking account potential recoveries parties amount includes estimated costs additional probable loss associated previously disclosed north brunswick township high school remediation site note selected quarterly financial data unaudited dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earningsloss net earningsloss attributable noncontrolling interest bms earningsloss per share basica earningsloss per share diluteda cash dividends declared per common share cash cash equivalents marketable securitiesb total assets longterm debtc equity dollars millions except per share data first quarter second quarter third quarter fourth quarter year total revenues gross margin net earnings net earnings attributable noncontrolling interest bms earnings per share basica earnings per share diluteda cash dividends declared per common share cash cash equivalents marketable securitiesb total assets longterm debtc equity earnings per share quarters may add amounts year period computed discrete basis b marketable securities includes current noncurrent assets c longterm debt includes current portion following specified items affected comparability results first second third fourth dollars millions quarter quarter quarter quarter year cost products solda marketing selling administrative license asset acquisition charges iprd impairments site exit costs research development provision restructuring litigation settlements divestiture gains royalties licensing income pension charges loss debt redemption income net increasedecrease pretax income income taxes items income taxes attributed us tax reform income taxes increasedecrease net earnings noncontrolling interest increasedecrease net earnings used diluted nongaap eps calculation first second third fourth dollars millions quarter quarter quarter quarter year cost products solda license asset acquisition charges iprd impairments site exit costs research development provision restructuring litigation settlements divestiture gains royalties licensing income pension charges intangible asset impairment income net increasedecrease pretax income income taxes increasedecrease net earnings specified items cost products sold accelerated depreciation asset impairment shutdown costs report independent registered public accounting firm shareholders board directors bristolmyers squibb company opinion financial statements audited accompanying consolidated balance sheets bristolmyers squibb company subsidiaries company december related consolidated statements earnings comprehensive income cash flows three years period ended december related notes collectively referred financial statements opinion financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity accounting principles generally accepted united states america also audited accordance standards public company accounting oversight board united states pcaob company 's internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission report dated february expressed unqualified opinion company 's internal control financial reporting basis opinion financial statements responsibility company 's management responsibility express opinion company 's financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion deloitte touche llp parsippany new jersey february served company 's auditor since item changes disagreements accountants accounting financial disclosure none item controls procedures evaluation disclosure controls procedures december management carried evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure controls procedures term defined exchange act rule ae based evaluation management concluded december disclosure controls procedures effective managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting supervision participation management including chief executive officer chief financial officer management assessed effectiveness internal control financial reporting december based framework internal controlintegrated framework issued committee sponsoring organizations treadway commission based assessment management concluded companys internal control financial reporting effective december provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance united states generally accepted accounting principles due inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp independent registered public accounting firm audited companys financial statements included report issued report effectiveness companys internal control financial reporting december included herein changes internal control financial reporting changes company 's internal control financial reporting quarter ended december materially affected reasonable likely materially affect company 's internal control financial reporting item b information none report independent registered public accounting firm shareholders board directors bristolmyers squibb company opinion internal control financial reporting audited internal control financial reporting bristolmyers squibb subsidiaries company december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso opinion company maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued coso also audited accordance standards public company accounting oversight board united states pcaob consolidated financial statements year ended december company report dated february expressed unqualified opinion consolidated financial statements basis opinion companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate deloitte touche llp parsippany new jersey february part iii item directors executive officers registrant reference made proxy statement filed march respect directors registrant incorporated herein reference made part hereof response information required item b information required item respect executive officers registrant included part ia reliance general instruction g instruction item b regulation sk item executive compensation reference made proxy statement filed march respect executive compensation incorporated herein reference made part hereof response information required item item security ownership certain beneficial owners management related stockholder matters reference made proxy statement filed march respect security ownership certain beneficial owners management incorporated herein reference made part hereof response information required item item certain relationships related transactions reference made proxy statement filed march respect certain relationships related transactions incorporated herein reference made part hereof response information required item item auditor fees reference made proxy statement filed march respect auditor fees incorporated herein reference made part hereof response information required item part iv item